Heteroquinoline-3-carboxamides as KCNQ2/3 modulators

ABSTRACT

The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

This application claims priority of U.S. Provisional Patent Application No. 61/730,542, filed on Nov. 28, 2012, and European Patent Application No. 12007990.0, filed on Nov. 28, 2012, the entire contents of which patent applications are incorporated herein by reference.

The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

The treatment of pain, in particular of neuropathic pain, is of great importance in medicine. There is a worldwide need for effective pain therapies. The urgent need for action for a target-orientated treatment of chronic and non-chronic states of pain appropriate for the patient, by which is to be understood the successful and satisfactory treatment of pain for the patient, is also documented in the large number of scientific works which have recently been published in the field of applied analgesics and of fundamental research into nociception.

A pathophysiological feature of chronic pain is the overexcitability of neurons. Neuronal excitability is influenced decisively by the activity of K⁺ channels, since these determine decisively the resting membrane potential of the cell and therefore the excitability threshold. Heteromeric K⁺ channels of the molecular subtype KCNQ2/3 (Kv7.2/7.3) are expressed in neurons of various regions of the central (hippocampus, amygdala) and peripheral (dorsal root ganglia) nervous system and regulate the excitability thereof. Activation of KCNQ2/3 K⁺ channels leads to a hyperpolarization of the cell membrane and, accompanying this, to a decrease in the electrical excitability of these neurons. KCNQ2/3-expressing neurons of the dorsal root ganglia are involved in the transmission of nociceptive stimuli from the periphery into the spinal marrow (Passmore et al., J. Neurosci. 2003; 23(18): 7227-36).

It has accordingly been possible to detect an analgesic activity in preclinical neuropathy and inflammatory pain models for the KCNQ2/3 agonist retigabine (Blackburn-Munro and Jensen, Eur J. Pharmacol. 2003; 460(2-3); 109-16; post et al., Naunyn Schmiedebergs Arch Pharmacol 2004; 369(4): 382-390).

The KCNQ2/3 K⁺ channel thus represents a suitable starting point for the treatment of pain; in particular of pain selected from the group consisting of chronic pain, acute pain, neuropathic pain, inflammatory pain, visceral pain and muscular pain (Nielsen et al., Eur J. Pharmacol. 2004; 487(I-3): 93-103), in particular of neuropathic and inflammatory pain.

Moreover, the KCNQ2/3 K⁺ channel is a suitable target for therapy of a large number of further diseases, such as, for example, migraine (US2002/0128277), cognitive diseases (Gribkoff, Expert Opin Ther Targets 2003; 7(6): 737-748), anxiety (Korsgaard et al., J Pharmacol Exp Ther. 2005, 14(1): 282-92), epilepsy (Wickenden et al., Expert Opin Ther Pat 2004; 14(4): 457-469; Gribkoff, Expert Opin Ther Targets 2008, 12(5): 565-81; Miceli et al., Curr Opin Pharmacol 2008, 8(1): 65-74), urinary incontinence (Streng et al., J Urol 2004; 172: 2054-2058), dependency (Hansen et al., Eur J Pharmacol 2007, 570(I-3): 77-88), mania/bipolar disorders (Dencker et al., Epilepsy Behav 2008, 12(1): 49-53) and dystonia-associated dyskinesias (Richter et al., Br J Pharmacol 2006, 149(6): 747-53).

Substituted compounds that have an affinity for the KCNQ2/3 K⁺ channel are e.g. known from the prior art (WO 2008/046582, WO 2010/046108). In particular, certain quinoline-3-carboxamides have been described for KCNQ modulation (WO 2010/102811, WO 2012/025236, WO 2012/025237, WO 2012/025238).

There is a demand for further compounds having comparable or better properties, not only with regard to affinity to KCNQ2/3 K⁺ channels per se (potency, efficacy).

Thus, it may be advantageous to improve the metabolic stability, the solubility in aqueous media or the permeability of the compounds. These factors can have a beneficial effect on oral bioavailability or can alter the PK/PD (pharmacokinetic/pharmacodynamic) profile; this can lead to a more beneficial period of effectiveness, for example. A weak or non-existent interaction with transporter molecules, which are involved in the ingestion and the excretion of pharmaceutical compositions, is also to be regarded as an indication of improved bioavailability and at most low interactions of pharmaceutical compositions. Furthermore, the interactions with the enzymes involved in the decomposition and the excretion of pharmaceutical compositions should also be as low as possible, as such test results also suggest that at most low interactions, or no interactions at all, of pharmaceutical compositions are to be expected.

In addition, it may be advantageous if the compounds show a high selectivity towards other receptors of the KCNQ family (specificity), e.g. towards KCNQ1, KCNQ3/5 or KCNQ4. A high selectivity may have a positive effect on the side effects profile: for example it is known that compounds which (also) have an affinity to KCNQ1 are likely to have a potential for cardial side effects. Therefore, a high selectivity towards KCNQ1 may be desirable. However, it may also be advantageous for the compounds to show a high selectivity towards other receptors. For instance, it may be advantageous for the compounds to show a low affinity for the hERG ion channel or the L-type calcium ion channel (phenylalkylamine-, benzothiazepin-, dihydropyridine-binding site) since these receptors are known to possibly have a potential for cardial side effects. Further, an improved selectivity towards binding to other endogenic proteins (i.e. receptors or enzymes) may result in a better side effects profile and, consequently to an improved tolerance.

It was therefore an object of the invention to provide new compounds having advantages over the compounds of the prior art. These compounds should be suitable in particular as pharmacological active ingredients in pharmaceutical compositions, preferably in pharmaceutical compositions for the treatment and/or prophylaxis of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K⁺ channels.

That object is achieved by the subject-matter described hereinbelow.

It has been found, surprisingly, that substituted compounds of the general formula (I) given below are suitable for the treatment of pain. It has also been found, surprisingly, that substituted compounds of the general formula (I) given below also have an excellent affinity for the KCNQ2/3 K⁺ channel and are therefore suitable for the prophylaxis and/or treatment of disorders and/or diseases that are mediated at least in part by KCNQ2/3 K⁺ channels. The substituted compounds thereby act as modulators, i.e. agonists or antagonists, of the KCNQ2/3 K⁺ channel.

In a first aspect, the present invention therefore relates to a compound of general formula (I),

wherein

-   A¹, A² and A³ independently of each other represent CR⁴, N, O, S or     N(CH₃), -   A⁴ represents CR⁴ or N, and -   n denotes 0 or 1, -   with the proviso, that -   at least one of A¹, A², A³ and A⁴ does not represent CR⁴, -   and with the proviso, that -   if n denotes 0, then precisely one of A¹, A² and A³ represents O, S     or N(CH₃), or -   if n denotes 1, then A¹, A² and A³ independently of each other     represent CR⁴ or N, -   R¹ represents     -   C₁₋₁₀-aliphatic residue, unsubstituted or mono- or         polysubstituted;     -   C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted and in each case optionally linked via         a C₁₋₈-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted;     -   aryl or heteroaryl, in each case unsubstituted or mono- or         polysubstituted and in each case optionally linked via a         C₁₋₈-aliphatic group, which in turn may be unsubstituted or         mono- or poly-substituted; -   R² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃;     C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue,     C(═O)—O—C₁₋₄-aliphatic residue, C(═O)—NH—C₁₋₄-aliphatic residue,     C(═O)—N(C₁₋₄-aliphatic residue)₂, O—C₁₋₄-aliphatic residue,     O—C(═O)—C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue,     S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue may be in each case be         unsubstituted or mono- or polysubstituted;     -   C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted and in each case optionally linked via         a C₁₋₄-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted; -   R³ represents     -   C₂₋₁₀-aliphatic residue, unsubstituted or mono- or         polysubstituted; or     -   C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted and in each case optionally linked via         a C₁₋₈-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted,     -   or     -   denotes S—R⁵, O—R⁶ or N(R⁷R⁸),     -   wherein     -   R⁵ and R⁶ in each case represent         -   C₁₋₁₀-aliphatic residue, unsubstituted or mono- or             polysubstituted;         -   C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered             heterocycloaliphatic residue, in each case unsubstituted or             mono- or polysubstituted and in each case optionally linked             via a C₁₋₈-aliphatic group, which in turn may be             unsubstituted or mono- or polysubstituted;         -   with the proviso, that if R⁵ or R⁶ denote a 3 to 10 membered             heterocycloaliphatic residue, than the 3 to 10 membered             heterocycloaliphatic residue is linked via a carbon atom,     -   R⁷ represents         -   C₁₋₁₀-aliphatic residue, unsubstituted or mono- or             polysubstituted;         -   C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered             heterocycloaliphatic residue, in each case unsubstituted or             mono- or polysubstituted and in each case optionally linked             via a C₁₋₈-aliphatic group, which in turn may be             unsubstituted or mono- or polysubstituted;             -   with the proviso that if R⁷ denotes 3 to 10 membered                 heterocycloaliphatic residue, the 3 to 10 membered                 heterocycloaliphatic residue is linked via a carbon                 atom; and     -   R⁸ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or         polysubstituted;     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 10 membered heterocycloaliphatic residue, unsubstituted or         mono- or polysubstituted;     -   and each R⁴ independently represents H, F; Cl; Br; I; CN; CF₃;         CHF₂; CH₂F; OCF₃; OCHF₂; OCH₂F; SCF₃; O—C₁₋₄-aliphatic residue,         C₁₋₄-aliphatic residue or S(═O)₂—C₁₋₄-aliphatic residue;         in which an “aliphatic group” and “aliphatic residue” may in         each case be branched or unbranched, saturated or unsaturated,         in which a “cycloaliphatic residue” and a “heterocycloaliphatic         residue” may in each case be saturated or unsaturated,         in which “mono- or polysubstituted” with respect to an         “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic         residue” and a “heterocycloaliphatic residue” relates, with         respect to the corresponding residues or groups, to the         substitution of one or more hydrogen atoms each independently of         one another by at least one substituent selected from the group         consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄ aliphatic         residue, N(C₁₋₄ aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue,         NH—S(═O)₂—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic         residue)-S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃,         O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH,         SCF₃, aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic         residue, S(═O)₂—O—C₁₋₄-aliphatic residue,         S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic         residue)₂, CN, CF₃, CHO, COOH, C₁₋₄-aliphatic residue,         C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue,         C₃₋₆-cycloaliphatic residue, 3 to 7 membered         heterocycloaliphatic residue, C(═O)NH₂, a         C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic         residue)₂;         in which “mono- or polysubstituted” with respect to “aryl” and a         “heteroaryl” relates, with respect to the corresponding         residues, to the substitution of one or more hydrogen atoms each         independently of one another by at least one substituent         selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,

NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄-aliphatic residue, N(C₁₋₄aliphatic residue)-C(═O)—C₁₋₄aliphatic residue, NH—S(═O)₂—C₁₋₄aliphatic residue, N(C₁₋₄aliphatic residue)-S(═O)₂—C₁₋₄ aliphatic residue, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, C(═O)H, C(═O)OH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH₂, C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and/or a physiologically acceptable salt.

Within the scope of this invention, the terms “aliphatic residue” or “aliphatic group” include acyclic saturated or unsaturated aliphatic hydrocarbon radicals, which can be branched or unbranched as well as unsubstituted or mono- or poly-substituted, having from 1 to 10 or from 1 to 8 or from 1 to 6 or from 1 to 4 or from 1 to 2 or from 2 to 6 carbon atoms, that is to say C₁₋₁₀-alkanyls, C₂₋₁₀-alkenyls and C₂₋₁₀-alkynyls or C₁₋₈-alkanyls, C₂₋₈-alkenyls and C₂₋₈-alkynyls or C₁₋₆-alkanyls, C₂₋₆-alkenyls and C₂₋₆-alkynyls or C₁₋₄-alkanyls, C₂₋₄-alkenyls and C₂₋₄-alkynyls or C₁₋₂-alkanyls, C₂-alkenyls and C₂-alkynyls or C₂₋₆-alkanyls, C₂₋₆-alkenyls and C₂₋₆-alkynyls. Alkenyls contain at least one C—C double bond and alkynyls contain at least one C—C triple bond. Alkyl is preferably selected from the group comprising methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, ethenyl(vinyl), ethynyl, propenyl, propynyl, butenyl, butynyl, pentenyl, pentynyl, hexenyl and hexynyl, heptenyl, heptynyl, octenyl, octynyl, nonenyl, nonynyl, decenyl and decynyl.

For the purposes of this invention, the terms “cycloaliphatic residue” or “C₃₋₁₀-cycloaliphatic residue” and “C₃₋₆-cycloaliphatic residue” denote cyclic aliphatic hydrocarbons having 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms or having 3, 4, 5 or 6 carbon atoms, wherein the hydrocarbons can be saturated or unsaturated (but not aromatic), unsubstituted or mono- or poly-substituted. The bonding of the cycloaliphatic residue to the general structure of higher order can take place via any desired and possible ring member of the cycloalkyl radical. The cycloaliphatic residue can also be fused with further saturated, (partially) unsaturated, (hetero)cycloaliphatic, aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. The cycloaliphatic residue radicals can further be bridged one or more times, as, for example, in the case of adamantyl, bicyclo[2.2.1]heptyl or bicyclo[2.2.2]octyl. Cycloalkyl is preferably selected from the group comprising cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl cyclononyl, cyclodecyl, adamantyl as well as

Preferred C₃₋₆-cycloaliphatic residues are selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl.

The term “3 to 10 membered heterocycloaliphatic residue” or “3 to 7 membered heterocycloaliphatic residue” or “heterocycloaliphatic residue” includes aliphatic saturated or unsaturated (but not aromatic) heterocycloaliphatic residues having preferentially from three to ten, that is to say 3, 4, 5, 6, 7, 8, 9 or 10, ring members or from three to seven, that is to say 3, 4, 5, 6 or 7, ring members in which at least one carbon atom, optionally also two or three carbon atoms, has been replaced by a heteroatom or heteroatom group in each case selected independently of one another from the group consisting of O, S, S(═O), S(═O)₂, N, NH and N(C₁₋₈-alkyl), preferably N(CH₃), wherein the ring members can be unsubstituted or mono- or poly-substituted. The bonding of the heterocycloaliphatic residue to the general structure of higher order can take place via any desired and possible ring member of the heterocycloaliphatic residue. The heterocycloaliphatic residues can also be fused with further saturated, (partially) unsaturated (hetero)cycloaliphatic or aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Heterocycloaliphatic residues are preferably selected from the group comprising azetidinyl, aziridinyl, azepanyl, azocanyl, diazepanyl, dithiolanyl, dihydroquinolinyl, dihydropyrrolyl, dioxanyl, dioxolanyl, dihydroindenyl, dihydropyridinyl, dihydrofuranyl, dihydroisoquinolinyl, dihydroindolinyl, dihydroisoindolyl, imidazolidinyl, isoxazolidinyl, morpholinyl, oxiranyl, oxetanyl, pyrrolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyranyl, tetrahydropyrrolyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, tetrahydroindolinyl, tetrahydrofuranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrahydropyridoindolyl, tetrahydronaphthyl, tetrahydrocarbolinyl, tetrahydroisoxazolopyridinyl, thiazolidinyl and thiomorpholinyl.

Within the scope of this invention, the term “aryl” denotes aromatic hydrocarbons having up to 14 ring members, inter alia phenyls and naphthyls. Each aryl radical can be unsubstituted or mono- or poly-substituted, it being possible for the aryl substituents to be identical or different and to be in any desired and possible position of the aryl. The aryl can be bonded to the general structure of higher order via any desired and possible ring member of the aryl radical. The aryl radicals can also be fused with further saturated, (partially) unsaturated, (hetero)cycloaliphatic, aromatic or heteroaromatic ring systems, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. Examples of fused aryl radicals are benzodioxolanyl and benzodioxanyl. Aryl is preferably selected from the group containing phenyl, 1-naphthyl and 2-naphthyl, each of which can be unsubstituted or mono- or poly-substituted. A particularly preferred aryl is phenyl, unsubstituted or mono- or poly-substituted.

The term “heteroaryl” denotes a 5- or 6-membered cyclic aromatic radical which contains at least 1 heteroatom, optionally also 2, 3, 4 or 5 heteroatoms, wherein the heteroatoms are in each case selected independently of one another from the group S, N and O and the heteroaryl radical can be unsubstituted or mono- or poly-substituted; in the case of substitution on the heteroaryl, the substituents can be identical or different and can be in any desired and possible position of the heteroaryl. Bonding to the general structure of higher order can take place via any desired and possible ring member of the heteroaryl radical. The heteroaryl can also be part of a bi- or poly-cyclic system having up to 14 ring members, wherein the ring system can be formed with further saturated, (partially) unsaturated, (hetero)-cycloaliphatic residue or aromatic or heteroaromatic rings, that is to say with cycloaliphatic residue, heterocycloaliphatic residue, aryl or heteroaryl, which can themselves be unsubstituted or mono- or poly-substituted. It is preferred for the heteroaryl radical to be selected from the group comprising benzo-furanyl, benzoimidazolyl, benzothienyl, benzothiadiazolyl, benzothiazolyl, benzotriazolyl, benzooxazolyl, benzooxadiazolyl, quinazolinyl, quinoxalinyl, carbazolyl, quinolinyl, dibenzofuranyl, dibenzothienyl, furyl(furanyl), imidazolyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isoquinolinyl, isoxazolyl, isothiazolyl, indolyl, naphthyridinyl, oxazolyl, oxadiazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pyrazolyl, pyridyl(2-pyridyl, 3-pyridyl, 4-pyridyl), pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, purinyl, phenazinyl, thienyl(thiophenyl), triazolyl, tetrazolyl, thiazolyl, thiadiazolyl and triazinyl. Furyl, pyridyl and thienyl are particularly preferred.

Within the scope of the invention, the expressions “linked via C₁₋₄-aliphatic group” or “linked via a C₁₋₈-aliphatic group” in relation to aryl, heteroaryl, heterocycloaliphatic residue or cycloaliphatic residue is understood that C₁₋₈-aliphatic group or C₁₋₄-aliphatic group and aryl or heteroaryl or heterocycloaliphatic residue or cycloaliphatic residue have the meanings defined above and the aryl or heteroaryl or heterocycloaliphatic residue or cycloaliphatic residue is bonded to the general structure of higher order via a C₁₋₄-aliphatic group or via a C₁₋₈-aliphatic group. The aliphatic group can in all cases be saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted. The C₁₋₄-aliphatic group is preferably selected from C₁₋₄-alkyl groups, preferably from the group comprising of —CH₂—, —CH₂CH₂—, —CH(CH₃)—, —CH₂CH₂CH₂—, —CH(CH₃)CH₂—, —CH(CH₂CH₃)—, —CH₂(CH₂)₂CH₂—, —CH(CH₃)CH₂CH₂—, —CH₂CH(CH₃)CH₂—, —CH(CH₃)CH(CH₃)—, —CH(CH₂CH₃)CH₂—, —C(CH₃)₂CH₂—, —CH(CH₂CH₂CH₃)—, —C(CH₃)(CH₂CH₃)—, —CH═CH—, —CH═CHCH₂—, —C(CH₃)═CH₂—, —CH═CHCH₂CH₂—, —CH₂CH═CHCH₂—, —CH═CHCH═CH—, —C(CH₃)═CHCH₂—, —CH═C(CH₃)CH₂—, —C(CH₃)═C(CH₃)—, —C(CH₂CH₃)═CH—, —C≡C—, —C≡CCH₂—, —C≡CCH₂CH₂—, —C≡CCH(CH₃)—, —CH₂C≡CCH₂— and —C≡CC(CH₃)₂—.

In relation with “aliphatic residue”, “aliphatic group”, “heterocycloaliphatic residue” and “cycloaliphatic residue”, the expression “mono- or poly-substituted” is understood as meaning within the scope of this invention the substitution of one or more hydrogen atoms one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄ aliphatic residue, N(C₁₋₄-aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue, NH—S(═O)₂—C₁₋₄-aliphatic residue, N(C₁₋₄-aliphatic residue)-S(═O)₂—C₁₋₄-aliphatic residue, ═O, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, CHO, COOH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH₂, a C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; wherein polysubstituted radicals are to be understood as being radicals that are substituted several times, for example two, three or four times, either on different atoms or on the same atom, for example three times on the same carbon atom, as in the case of CF₃ or CH₂CF₃, or at different places, as in the case of CH(OH)—CH═CH—CHCl₂. A substituent can itself optionally be mono- or poly-substituted. Polysubstitution can take place with the same or with different substituents.

Preferred substituents of “aliphatic residue”, “aliphatic group”, “heterocycloaliphatic residue” or “cycloaliphatic residue” are selected from the group comprising F, Cl, Br, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄aliphatic residue, NH—S(═O)₂—C₁₋₄-aliphatic residue, ═O, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, COOH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(═O)NH₂, C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂.

In relation with “aryl” and “heteroaryl”, the term “mono- or poly-substituted” is understood within the scope of this invention as meaning the substitution of one or more hydrogen atoms of the ring system one or more times, for example two, three or four times, in each case independently of one another, by substituents selected from the group comprising

F, Cl, Br, I, NO₂, NH₂,

NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄-aliphatic residue, N(C₁₋₄-aliphatic residue)-C(═O)—C₁₋₄-aliphatic residue, NH—S(═O)₂—C₁₋₄-aliphatic residue, N(C₁₋₄aliphatic residue)-S(═O)₂—C₁₋₄-aliphatic residue, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, C(═O)H, C(═O)OH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH₂, C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; on one atom or optionally on different atoms, wherein a substituent can itself optionally be mono- or poly-substituted. Polysubstitution is carried out with the same or with different substituents.

Preferred “aryl” and “heteroaryl” substituents are F; Cl; Br; CF₃; CN; C₁₋₄-aliphatic residue; phenyl; naphthyl; pyridyl; thienyl; furyl; C₃₋₆-cycloaliphatic residue; 3 to 7 membered heterocycloaliphatic residue; C(═O)—C₁₋₄-aliphatic residue; CC₂H; C(═O)—O—C₁₋₄-aliphatic residue; CONH₂; C(═O)—NH(C₁₋₄-aliphatic residue); C(═O)—N(C₁₋₄-aliphatic residue)₂; OH; O—C₁₋₄-aliphatic residue; OCF₃; O—C(═O)—C₁₋₄-aliphatic residue; NH₂; NH(C₁₋₄-aliphatic residue); N(C₁₋₄-aliphatic residue)₂; N(H)C(═O)—C₁₋₄-aliphatic residue; S—C₁₋₈-alkyl; SCF₃; S(═O)₂C₁₋₄-aliphatic residue; S(═O)₂—N(H)C₁₋₄-aliphatic residue.

The compounds according to the invention are defined by substituents, for example by R^(A), R^(B) and R^(C) (1st generation substituents), which are themselves optionally substituted (2nd generation substituents). Depending on the definition, these substituents of the substituents can in turn themselves be substituted (3rd generation substituents). If, for example, R^(A)=aryl (1st generation substituent), aryl can itself be substituted, for example by C₁₋₄-aliphatic residue (2nd generation substituent). This yields the functional group aryl-C₁₋₄-aliphatic residue. C₁₋₄-aliphatic residue can then in turn itself be substituted, for example by Cl (3rd generation substituent). Overall, this then yields the functional group aryl-C₁₋₄-aliphatic residue-Cl.

In a preferred embodiment, however, the 3rd generation substituents cannot themselves be substituted, that is to say there are no 4th generation substituents.

In another preferred embodiment, the 2nd generation substituents cannot themselves be substituted, that is to say there are not even any 3rd generation substituents. In other words, in this embodiment, for example in the case of the general formula (I), the functional groups for R¹ to R¹⁴ can in each case optionally be substituted, but the substituents in each case cannot themselves be substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry an aryl or heteroaryl radical, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example an aryl or heteroaryl, in each case unsubstituted or mono- or poly-substituted. Both these aryl or heteroaryl radicals and the aromatic ring systems so formed can optionally be fused with C₃₋₁₀-cycloaliphatic residue or heterocycloaliphatic residue, in each case saturated or unsaturated, that is to say with a C₃₋₁₀-cycloaliphatic residue such as cyclopentyl or with a heterocycloaliphatic residue such as morpholinyl, it being possible for the C₃₋₁₀-cycloaliphatic residue or heterocycloaliphatic residue radicals so fused to be unsubstituted or mono- or poly-substituted.

In some cases, the compounds according to the invention are defined by substituents which are or carry a C₃₋₁₀-heterocycloaliphatic residue or heterocycloaliphatic residue, in each case unsubstituted or mono- or poly-substituted, or which, together with the carbon atom(s) or heteroatom(s) joining them as ring member(s), form a ring, for example a C₃₋₁₀-cycloaliphatic residue or heterocycloaliphatic residue, in each case unsubstituted or mono- or poly-substituted. Both these C₃₋₁₀-cycloaliphatic or heterocycloaliphatic residue and the aliphatic ring systems formed can optionally be fused with aryl or heteroaryl, that is to say with an aryl such as phenyl or with a heteroaryl such as pyridyl, it being possible for the aryl or heteroaryl radicals so fused to be unsubstituted or mono- or poly-substituted.

Within the scope of the present invention, the symbol

used in formulae denotes a linking of a corresponding radical to the general structure of higher order.

The expression “salt formed with a physiologically acceptable acid” is understood within the scope of this invention as meaning salts of the active ingredient in question with inorganic or organic acids that are physiologically acceptable—in particular when used in humans and/or mammals. The hydrochloride is particularly preferred.

Physiologically acceptable salts with cations or bases are salts of the compound in question—in the form of the anion with at least one, preferably inorganic—cation that are physiologically acceptable—in particular when used in humans and/or mammals.

In one embodiment of present invention, the compound according to general formula (I), is characterized in that

-   A¹, A² and A³ independently of each other represent CR⁴, N, O, S or     N(CH₃), -   A⁴ represents CR⁴ or N, and -   n denotes 0 or 1, -   with the proviso, that -   at least one of A¹, A², A³ and A⁴ does not represent CR⁴, -   and with the proviso, that -   if n denotes 0, then precisely one of A¹, A² and A³ represents O, S     or N(CH₃), or -   if n denotes 1, then A¹, A² and A³ independently of each other     represent CR⁴ or N, -   R¹ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic     residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic     residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,     C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH,         C₃₋₆-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₈-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10         membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₈-aliphatic group, which in turn may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   or denotes aryl or heteroaryl, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃,         C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₈-cycloaliphatic residue, 3         to 7 membered heterocycloaliphatic residue,

-   -    benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl may in each case may be unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic         residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃,         C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   and wherein the aryl or the heteroaryl residue may in each case         be optionally linked via a C₁₋₈-aliphatic group, which in turn         may be unsubstituted or mono- or polysubstituted with at least         one substituent selected from the group consisting of F, Cl, Br,         I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN and C(═O)OH,

-   R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic     residue, S—C₁₋₄-aliphatic residue, O—C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue may be in each case be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   C₃₋₈-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted and in each case optionally linked via         a C₁₋₄-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN and C(═O)OH,

-   R³ denotes C₂₋₁₀-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic     residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic     residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,     C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered         heterocycloaliphatic residue may in each case optionally linked         via a C₁₋₈-aliphatic group, which in turn may be unsubstituted         or mono- or polysubstituted with at least one substituent         selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   or     -   denotes S—R⁵, O—R⁶ or N(R⁷R⁸),     -   wherein     -   R⁵ and R⁶ in each case represent C₁₋₁₀-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or in each case represent C₃₋₁₀-cycloaliphatic residue or 3 to         10 membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue,         C(═O)—OH, C₃₋₈-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₈-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3         to 10 membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₈-aliphatic group, which in turn may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   on the condition that if R⁵ or R⁶ denote a 3 to 10 membered         heterocycloaliphatic residue, the 3 to 10 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   R⁷ denotes a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue and         C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,     -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH,         C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₈-cycloaliphatic residue and         3 to 7 membered heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₈-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3         to 10 membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₈-aliphatic group, which in turn may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue,         C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, on the         condition that if R⁷ denotes a 3 to 10 membered         heterocycloaliphatic residue, the 3 to 10 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   and     -   R⁸ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 10 membered heterocycloaliphatic residue, unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH,         C₃₋₈-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₈-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH, and     -   wherein the 3 to 10 membered heterocycloaliphatic residue formed         by R⁷ and R⁸ together with the nitrogen atom connecting them may         optionally be condensed with aryl or heteroaryl, wherein the         aryl or heteroaryl residues condensed in this way can for their         part be respectively unsubstituted or mono- or polysubstituted         with at least one substituent selected from the group consisting         of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),         N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃,         SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic         residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅,         C₃₋₆-cycloaliphatic residue, 3 to 7 membered         heterocycloaliphatic residue,

-   -    benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and         -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl             and oxazolyl may in each case may be unsubstituted or mono-             or polysubstituted with at least one substituent selected             from the group consisting of F, Cl, Br, I, NO₂, NH₂,             NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,             O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH,             SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic             residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and             C(═O)OC₂H₅, and         -   wherein the C₃₋₆ cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),             N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)—OH,

-   and

-   each R⁴ independently represents H, F; Cl; Br; I; CN; CF₃; CHF₂;     CH₂F; OCF₃; OCHF₂; OCH₂F; SCF₃; O—C₁₋₄-aliphatic residue,     C₁₋₄-aliphatic residue or S(═O)₂—C₁₋₄-aliphatic residue.

Within the scope of the present invention, the central structural element of general formula (I),

represents a bicyclic [5,6] (for n=0) or a bicyclic [6,6] (for n=1) heteroaryl residue. The heteroaryl residue is aromatic as depicted by the dashed bond presentation.

If n represents 1, then central structural element in general formula (I) represents a a bicyclic [6,6] heteroaryl residue (I-1):

If n represents O, then the partial structure in general formula (I) represents a bicyclic [5,6] heteroaryl residue (I-2) or (I-3) or (I-4):

To retain aromaticity of the 5-membered heterocycle, it is understood within the scope of the invention, that, if n denotes 0 and A³ represents O or S or NR⁸, the compound according to general formula (I) is represented by formula (I-2),

that, if n denotes 0 and A¹ represents O or S or NR⁸, the compound according to general formula (I) is represented by formula (I-3), and

that, if n denotes 0 and A² represents O or S or NR⁸, the compound according to general formula (I) is represented by formula (I-4).

In another embodiment of the invention, the compound according to general formula (I) is characterized in that

n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents CR⁴ (formula (I-1a)),

or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents CR⁴ and A⁴ represents CR⁴ (formula (I-1b)),

or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents CR⁴ (formula (I-1c)),

or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents N (formula (I-1d)),

or n denotes 1 and A¹ represents N, A² represents N, A³ represents CR⁴ and A³ represents CR⁴ (formula (I-1e)),

or n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents N and A³ represents CR⁴ (formula (I-1f)),

or n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents N (formula (I-1g)),

or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents CR⁴ and A⁴ represents N (formula (I-1h)),

or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents N and A⁴ represents CR⁴ (formula (I-1i)),

or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents N and A³ represents N (formula (I-1j)),

or n denotes 0 and A¹ represents S, A² represents CR⁴ and A³ represents CR⁴ (formula (I-3a)),

or n denotes 0 and A¹ represents S, A² represents CR⁴ and A³ represents N (formula (I-3b)),

or n denotes 0 and A¹ represents O, A² represents CR⁴ and A³ represents CR⁴ (formula (I-3c)),

or n denotes 0 and A¹ represents O, A² represents CR⁴ and A³ represents N (formula (I-3d)),

or n denotes 0 and A¹ represents CR⁴, A² represents CR⁴ and A³ represents S (formula (I-2a)),

or n denotes 0 and A¹ represents N, A² represents CR⁴ and A³ represents S (formula (I-2b)),

or n denotes 0 and A¹ represents CR⁴, A² represents CR⁴ and A³ represents O (formula (I-2c)),

or n denotes 0 and A¹ represents N, A² represents CR⁴ and A³ represents O (formula (I-2d)),

In preferred embodiment of the invention, the compound according to general formula (I) is characterized in that

n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents CR⁴ (I-1a);

or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents CR⁴ and A⁴ represents CR⁴ (I-1b);

or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents N and A⁴ represents CR⁴ (I-1c);

or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents N (I-1d);

or n denotes 0 and A¹ represents CR⁴, A² represents CR⁴, and A³ represents S (I-2a);

or n denotes 0 and A¹ represents S, A² represents CR⁴ and A³ represents CR⁴ (I-3a).

In a preferred embodiment of the invention, the compound according to general formula (I) is characterized in that

-   R¹ denotes C₁₋₁₀-aliphatic residue, preferably C₁₋₈-aliphatic     residue, unsubstituted or mono- or polysubstituted with at least one     substituent selected from the group consisting of F, Cl, Br, I, NO₂,     NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,     O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue,     S(═O)₂—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and     C(═O)—OH,     -   preferably denotes C₁₋₁₀-aliphatic residue, more preferably a         C₁₋₈-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue and C(═O)—OH,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂, an         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH, C₃₋₆         cycloaliphatic residue, and 3 to 7 membered heterocycloaliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,             and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, an NH(C₁₋₄-aliphatic residue), an             N(C₁₋₄-aliphatic residue)₂, OH, ═O, an O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)OH,     -   and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10         membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₄ aliphatic group, preferably a C₁₋₄         aliphatic group, which in turn may be unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue and C(═O)OH,     -   or denotes aryl or heteroaryl, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃,         C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3         to 7 membered heterocycloaliphatic residue,

-   -    benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,             and         -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl             and oxazolyl may in each case may be unsubstituted or mono-             or polysubstituted with at least one substituent selected             from the group consisting of F, Cl, Br, I, NO₂, NH₂,             NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,             O—C₁₋₄ aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH,             SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic             residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and             C(═O)OC₂H₅, and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),             N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)OH,     -   and wherein the aryl or the heteroaryl residue may in each case         be optionally linked via a C₁₋₄-aliphatic group, which in turn         may be unsubstituted or mono- or polysubstituted with at least         one substituent selected from the group consisting of F, Cl, Br,         I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN and C(═O)OH.

In a further embodiment of the invention, the compound according to general formula (I), the residue

-   R¹ represents the partial structure (T1)

-   wherein -   m denotes 0, 1, 2, 3 or 4, preferably denotes 0, 1, 2 or 3, more     preferably denotes 0, 1, or 2, -   R^(1a) and R^(1b) each independently of one another represent H, F,     Cl, Br, I, NO₂, NH₂, NH(C₁₋₄ aliphatic residue), N(C₁₋₄-aliphatic     residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄     aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue or C(═O)—OH, or     together denote ═O     -   preferably each independently of one another represent H, F, Cl,         Br, I, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic         residue, or together denote ═O,     -   more preferably each independently of one another represent H,         F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic         residue, or together denote ═O,     -   even more preferably each independently of one another represent         H, F, OH, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, or         together denote ═O, and -   R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic     residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic     residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue,     S(═O)₂—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and     C(═O)—OH,     -   preferably denotes C₁₋₄-aliphatic residue, unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   or denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH,         C₃₋₆-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue, preferably when m is ≠0,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,             and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),             N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)—OH,     -   or denotes     -   —preferably when m is 0 or 2, more preferably when m is 0—     -   aryl or heteroaryl, in each case unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃,         C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered         heterocycloaliphatic residue,

-   -    benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl,     -   preferably when m is =0,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,             and         -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl             and oxazolyl may in each case may be unsubstituted or mono-             or polysubstituted with at least one substituent selected             from the group consisting of F, Cl, Br, I, NO₂, NH₂,             NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,             O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic             residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃,             C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),             N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)OH.

Preferably,

-   R¹ represents the partial structure (T1), -   wherein -   m denotes 0, 1, or 2, -   R^(1a) and R^(1b) each independently of one another represent H, F,     Cl, Br, I, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, -   and -   R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and     C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, CF₃ and         O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic         residue, CF₃ and C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, CF₃ and         unsubstituted O—C₁₋₄-aliphatic residue,     -   or     -   denotes aryl or heteroaryl, in each case unsubstituted or mono-         or polysubstituted with at least one substituent selected from         the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic         residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃,         C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3         to 7 membered heterocycloaliphatic residue, benzyl, phenyl,         thienyl or pyridyl,     -   wherein benzyl, phenyl, thienyl and pyridyl may in each case may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic         residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃ C₁₋₄-aliphatic         residue and C(═O)OH.

In a further preferred embodiment of the compound according to general formula (I), the residue

-   R¹ represents the partial structure (T1), -   wherein -   m is 0, 1 or 2, preferably 0 or 2, more preferably 2, and -   R^(1a) and R^(1b) each independently of one another represent H, F,     OH, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, preferably     H, F, OH, CH₃ or OCH₃; -   R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, CN, OH, unsubstituted     O—C₁₋₄-aliphatic residue, CF₃ and unsubstituted C₁₋₄-aliphatic     residue, preferably denotes C₁₋₄-aliphatic residue, unsubstituted or     mono- or polysubstituted with at least one substituent selected from     the group consisting of F, Cl, Br, I, unsubstituted O—C₁₋₄-aliphatic     residue, CF₃, and unsubstituted C₁₋₄-aliphatic residue,     -   or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, unsubstituted         O—C₁₋₄-aliphatic residue, CF₃, and unsubstituted C₁₋₄-aliphatic         residue, -   or -   wherein -   m is 0 or 2, more preferably 0, and -   R^(1a) and R^(1b) each independently of one another represent H, F,     OH, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, preferably     H, F, OH, CH₃ or OCH₃; and -   R^(1c) denotes aryl or heteroaryl, in each case unsubstituted or     mono- or polysubstituted with at least one substituent selected from     the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue,     OCF₃, OCF₂H, SCF₃, NO₂, N(C₁₋₄-aliphatic residue)₂,

-    CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃,     C(═O)OC₂H₅ and phenyl,     -   preferably denotes aryl or heteroaryl, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic         residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅ and phenyl,         -   wherein phenyl may be unsubstituted or mono- or             polysubstituted, preferably unsubstituted or mono- or             disubstituted with at least one substituent selected from             the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic             residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃,             C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, preferably with at             least one substituent selected from the group consisting of             F, Cl, CH₃, OCH₃, CF₃ and OCF₃.

Preferably,

-   R¹ represents the partial structure (T1), -   wherein -   m denotes 1 or 2, -   R^(1a) and R^(1b) represent H, -   R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and     C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic         residue, CF₃ and C₁₋₄-aliphatic residue, -   or -   m denotes 0 and -   R^(1c) denotes aryl or heteroaryl, in each case unsubstituted or     mono- or polysubstituted with at least one substituent selected from     the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue,     OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅,     C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered     heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl,     -   wherein benzyl, phenyl, thienyl and pyridyl, may in each case         may be unsubstituted or mono- or polysubstituted with at least         one substituent selected from the group consisting of F, Cl, Br,         I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic         residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃ C₁₋₄-aliphatic         residue and C(═O)OH.

In another embodiment of the invention, the compound according to general formula (I) is characterized in that

-   R² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃;     C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue, O—C₁₋₄-aliphatic     residue,     -   wherein the C₁₋₄ aliphatic residue may be in each case be         unsubstituted or mono- or polysubstituted;     -   C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted and in each case optionally linked via         a C₁₋₄ aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted.

Preferably,

-   R² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; a     C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue, O—C₁₋₄-aliphatic     residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         ═O, OH and unsubstituted O—C₁₋₄-aliphatic residue,     -   C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, ═O, OH,         C₁₋₄-aliphatic residue and O—C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         ═O, OH, and unsubstituted O—C₁₋₄-aliphatic residue,     -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7         membered heterocycloaliphatic residue may in each case be         optionally linked via a C₁₋₄-aliphatic group, which in turn may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         ═O, OH, unsubstituted C₁₋₄-aliphatic residue and unsubstituted         aliphatic residue.

More preferably,

-   R² represents H; F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃;     C₁₋₄-aliphatic residue, a S—C₁₋₄-aliphatic residue, O—C₁₋₄-aliphatic     residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         ═O, OH and unsubstituted O—C₁₋₄-aliphatic residue,     -   cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl,         piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl,         preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,         in each case unsubstituted or mono- or polysubstituted with at         least one substituent selected from the group consisting of F,         Cl, Br, I, ═O, OH, unsubstituted C₁₋₄-aliphatic residue and         unsubstituted O—C₁₋₄-aliphatic residue,     -   and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,         pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl or         piperidinyl may in each case be optionally linked via an         C₁₋₄-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, unsubstituted         C₁₋₄-aliphatic residue and unsubstituted O—C₁₋₄-aliphatic         residue.

Even more preferably,

-   R² represents H, F, Cl, Br, I, CN, CF₃, NO₂, OCF₃, SCF₃, CH₃,     CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, CH₂(CH₂)₂CH₃, CH₂CH(CH₃)₂,     CH(CH₃)CH₂CH₃, C(CH₃)₃, OCH₃, OCH₂CH₃, O—(CH₂)₂—OCH₃, O—(CH₂)₂OH;     SCH₃, SCH₂CH₃, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

Still more preferably,

-   R² is selected from the group consisting of H, F, Cl, CN, CF₃, OCF₃,     SCF₃, CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, C(CH₃)₃, cyclopropyl; OCH₃     and OCH₂CH₃.

In particular,

-   R² is selected from the group consisting of H, F, Cl, CF₃, CF₃, CH₃,     CH₂CH₃, CH(CH₃)₂, cyclopropyl and OCH₃.

In another embodiment of the invention, the compound according to general formula (I) is characterized in that

-   R² represents C₁₋₄-aliphatic residue, preferably CH₃.

In another particular preferred embodiment of the invention, the compound according to general formula (I) is characterized in that R² is ≠H.

In another embodiment of the present invention, the compound according to general formula (I) is characterized in that

-   R³ denotes C₂₋₁₀-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic     residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic     residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,     C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and         wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered         heterocycloaliphatic residue may in each case optionally linked         via a C₁₋₄-aliphatic group, which in turn may be unsubstituted         or mono- or polysubstituted with at least one substituent         selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   or     -   denotes S—R⁵, O—R⁶ or N(R⁷R⁸),     -   wherein     -   R⁵ and R⁶ in each case represent C₁₋₆-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or in each case represent C₃₋₆-cycloaliphatic residue or 3 to 7         membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue,         C(═O)OH, C₃₋₆-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), an N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH, and     -   wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered         heterocycloaliphatic residue may in each case optionally linked         via a C₁₋₄-aliphatic group, which in turn may be unsubstituted         or mono- or polysubstituted with at least one substituent         selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,     -   on the condition that if R⁵ or R⁶ denote a 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   R⁷ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, and         C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH,         C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, and         a 3 to 7 membered heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)—OH, and     -   wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered         heterocycloaliphatic residue may in each case optionally linked         via a C₁₋₄-aliphatic group, which in turn may be unsubstituted         or mono- or polysubstituted with at least one substituent         selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, OCF₃,         SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic         residue and C(═O)OH,     -   on the condition that if R¹¹ denotes a 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom, and     -   R⁸ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic         residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,         C₁₋₄-aliphatic residue and C(═O)OH,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 10 membered heterocycloaliphatic residue, unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, NO₂, NH₂,         NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic         residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH,         C₃₋₆-cycloaliphatic residue and 3 to 7 membered         heterocycloaliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic         residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and         C(═O)OH, and     -   wherein the 3 to 10 membered heterocycloaliphatic residue formed         by R¹¹ and R¹² together with the nitrogen atom connecting them         may optionally be condensed with aryl or heteroaryl, wherein the         aryl or heteroaryl residues condensed in this way can for their         part be respectively unsubstituted or mono- or polysubstituted         with at least one substituent selected from the group consisting         of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),         N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃,         SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic         residue, C(═O)—OH, C(═O)—CH₃, C(═O)—C₂H₅, C(═O)—OCH₃ and         C(═O)—OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered         heterocycloaliphatic residue,

-   -    benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and         oxazolyl,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,         -   and         -   wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl             and oxazolyl may in each case may be unsubstituted or mono-             or polysubstituted with at least one substituent selected             from the group consisting of F, Cl, Br, I, NO₂, NH₂,             NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH,             O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH,             SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic             residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and             C(═O)OC₂H₅, and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue),             N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic             residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN,             C₁₋₄-aliphatic residue and C(═O)OH.

Preferably,

-   R³ denotes a C₂₋₆-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue,     OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN and C₁₋₄-aliphatic     residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   or denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄         aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄ aliphatic residue,         CF₃, CN and C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7         membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₄-aliphatic group, which in turn may         be unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN, and         C₁₋₄-aliphatic residue. -   or -   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case represent C₁₋₈-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, Br, I,         OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃,         S—C₁₋₄-aliphatic residue, NH(C₁₋₄-aliphatic residue),         N(C₁₋₄-aliphatic residue)₂, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, CF₃ and O—C₁₋₄-aliphatic residue,     -   or in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7         membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7         membered heterocycloaliphatic residue may in each case         optionally linked via a C₁₋₄-aliphatic group, preferably a         C₁₋₄-aliphatic group, which in turn may be unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, CF₃, CN, and C₁₋₄-aliphatic residue,     -   on the condition that if R⁵ or R⁶ denotes a 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom, -   or -   R³ denotes N(R⁷R⁸),     -   wherein     -   R⁷ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or denotes a C₃₋₆-cycloaliphatic residue or a 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃, and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered         heterocycloaliphatic residue may in each case be linked,         preferably is linked, via a C₁₋₄-aliphatic group, which in turn         may be unsubstituted or mono- or polysubstituted with at least         one substituent selected from the group consisting of F, Cl, OH,         ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and         C₁₋₄-aliphatic residue,     -   on the condition that if R⁷ denotes a 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   and wherein     -   R⁸ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue,         OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 10 membered heterocycloaliphatic residue, preferably a 3 to         7 membered heterocycloaliphatic residue, more preferably         selected from the group consisting of morpholinyl, piperidinyl,         pyrrolidinyl, azetidinyl and piperazinyl, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN, and         C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, Br,             I, OH, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   and wherein the 3 to 10 membered heterocycloaliphatic residue         formed by R⁷ and R⁸ together with the nitrogen atom connecting         them may optionally be condensed with aryl or heteroaryl,         preferably with phenyl or pyridyl,     -   wherein the aryl or heteroaryl residues condensed in this way         can for their part be respectively unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃,         SCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C₃₋₆         cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic         residue,

-   -    benzyl, phenyl, thienyl, and pyridyl,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH,         OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and     -   wherein benzyl, phenyl, thienyl, and pyridyl, may in each case         may be unsubstituted or mono- or polysubstituted with at least         one substituent selected from the group consisting of F, Cl, OH,         O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SCF₃, CF₃,         CN, C₁₋₄-aliphatic residue, and C(═O)OH, and     -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered         heterocycloaliphatic residue may in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue         and C(═O)OH.

More preferably,

-   R³ denotes C₂₋₆-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃,     CF₃ and C₁₋₄-aliphatic residue     -   wherein the C₁₋₄-aliphatic residue in each case is         unsubstituted,     -   or denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄ aliphatic         residue, OCF₃, CF₃ and C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with OH or         unsubstituted O—C₁₋₄-aliphatic residue.     -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7         membered heterocycloaliphatic residue may in each case         optionally linked via a unsubstituted C₁₋₄-aliphatic group, -   or -   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case denote C₁₋₆-aliphatic residue,         -   unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃ and C₁₋₄-aliphatic             residue,             -   wherein the C₁₋₄-aliphatic residue in each case may be                 unsubstituted or mono- or polysubstituted with at least                 one substituent selected from the group consisting of F,                 Cl, OH, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7         membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄ aliphatic residue, OCF₃, CF₃, and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and     -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered         heterocycloaliphatic residue in each case may be linked,         preferably is linked, via an unsubstituted C₁₋₄-aliphatic group,         on the condition that if R⁵ or R⁶ denotes a 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom, -   or -   R³ denotes N(R⁷R⁸),     -   wherein     -   R⁷ denotes C₁₋₆-aliphatic residue,         -   unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, and C₁₋₄-aliphatic             residue         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   or     -   R⁷ denotes C₃₋₇-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄ aliphatic         residue, OCF₃, CF₃, and a C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and unsubstituted O—C₁₋₄-aliphatic residue, and         -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10             membered heterocycloaliphatic residue may be linked via an             unsubstituted C₁₋₄-aliphatic group,         -   on the condition that if R⁵ denotes a 3 to 7 membered             heterocycloaliphatic residue, the 3 to 7 membered             heterocycloaliphatic residue is linked via a carbon atom,     -   and     -   R⁸ denotes unsubstituted C₁₋₄-aliphatic residue,         -   preferably selected from the group consisting of methyl,             ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl and             tert.-butyl, more preferably selected from the group             consisting of methyl and ethyl     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 7 membered heterocycloaliphatic residue, preferably         selected from the group consisting of morpholinyl, piperidinyl,         pyrrolidinyl, and azetidinyl, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue,         OCF₃, CF₃, CN, and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and unsubstituted O—C₁₋₄-aliphatic residue,     -   and wherein the 3 to 7 membered heterocycloaliphatic residue         formed by R⁷ and R⁸ together with the nitrogen atom connecting         them may optionally be fused with phenyl or pyridyl, wherein the         phenyl or pyridyl residues fused in this way can for their part         be respectively unsubstituted or mono- or polysubstituted with         at least one substituent selected from the group consisting of         F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN,         C₁₋₄-aliphatic residue, benzyl, phenyl, and pyridyl,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             and unsubstituted O—C₁₋₄-aliphatic residue, and         -   wherein benzyl, phenyl, and pyridyl, may in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl,             OCH₃, OCF₃, CF₃, and C₁₋₄-aliphatic residue.

Even more preferably,

-   R³ denotes C₂₋₆-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃,     SCF₃, CF₃ and C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with OH or             O—C₁₋₄-aliphatic residue,         -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7             membered heterocycloaliphatic residue may in each case             optionally linked via a C₁₋₄-aliphatic group, -   or -   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case denote C₁₋₆-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7         membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,         -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7             membered heterocycloaliphatic residue in each case may be             linked via an unsubstituted C₁₋₄-aliphatic group,         -   on the condition that if R⁵ or R⁶ denotes 3 to 7 membered             heterocycloaliphatic residue, the 3 to 7 membered             heterocycloaliphatic residue is linked via a carbon atom, -   or -   R³ denotes N(R⁷R⁸),     -   wherein     -   R⁷ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue,         OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,     -   and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7         membered heterocycloaliphatic residue is in each case linked via         a unsubstituted C₁₋₄-aliphatic group,     -   on the condition that if R⁷ denotes 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   and     -   R⁸ in each case denotes unsubstituted C₁₋₄-aliphatic residue,     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 7 membered heterocycloaliphatic residue, unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,         -   and wherein the 3 to 7 membered heterocycloaliphatic residue             formed by R⁷ and R⁸ together with the nitrogen atom             connecting them may optionally be condensed with phenyl or             pyridyl, wherein the phenyl or pyridyl residues condensed in             this way can for their part be respectively unsubstituted or             mono- or polysubstituted with at least one substituent             selected from the group consisting of F, Cl, OH,             O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN,             C₁₋₄-aliphatic residue, C(═O)OH, benzyl, phenyl, and             pyridyl,             -   wherein the C₁₋₄-aliphatic residue in each case may be                 unsubstituted or mono- or polysubstituted with at least                 one substituent selected from the group consisting of F,                 Cl, OH and O—C₁₋₄-aliphatic residue, and             -   wherein benzyl, phenyl, and pyridyl, may in each case                 may be unsubstituted or mono- or polysubstituted with at                 least one substituent selected from the group consisting                 of F, Cl, OCH₃, OCF₃, OCH₂CH₂OH, OCH₂CH₂OCH₃, SCF₃, CF₃                 and C₁₋₄-aliphatic residue.

More preferably,

-   R³ denotes CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, CH₂(CH₂)₂CH₃, CH₂CH(CH₃)₂,     CH(CH₃)CH₂CH₃, C(CH₃)₃, CH₂(CH₂)₃CH₃, CH₂CH₂CH(CH₃)₂, CH₂C(CH₃)₃,     CH₂(CH₂)₄CH₃, CH═CH₂ or CH₂CH═CH₂,     -   in each case unsubstituted or mono- or polysubstituted with at         least one substituent selected from the group consisting of F,         Cl, OH, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic         residue, preferably in each case unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, and an O—C₁₋₄-aliphatic residue,         preferably OCH₃, more preferably in each case unsubstituted,         -   wherein the C₁₋₄-aliphatic residue in each case is             unsubstituted,     -   or denotes cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,         oxetanyl, piperidinyl, tetrahydrofuranyl, or tetrahydropyranyl,     -   preferably denotes cyclopropyl or tetrahydropyranyl,     -   more preferably cyclopropyl,     -   in each case unsubstituted or mono- or polysubstituted with at         least one substituent selected from the group consisting of F,         Cl, OH, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic         residue,     -   preferably in each case unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl and O—C₁₋₄-aliphatic residue,         preferably OCH₃, more preferably in each case unsubstituted,         -   wherein the C₁₋₄-aliphatic residue in each case is             unsubstituted,     -   and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,         oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl         may in each case be optionally bridged via an unsubstituted         C₁₋₄-aliphatic group, preferably via an unsubstituted         C₁₋₂-aliphatic group, -   or -   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case denote CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂,         CH₂(CH₂)₂CH₃, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃, C(CH₃)₃, CH₂(CH₂)₃CH₃,         CH₂CH₂CH(CH₃)₂, CH₂C(CH₃)₃, CH₂(CH₂)₄CH₃, CH═CH₂ or CH₂CH═CH₂ in         each case unsubstituted or mono- or polysubstituted with at         least one substituent selected from the group consisting of F,         Cl, OH, and O—C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case is             unsubstituted,     -   or in each case denote cyclopropyl, cyclobutyl, cyclopentyl         cyclohexyl, oxetanyl, piperidinyl, tetrahydrofuranyl, or         tetrahydropyranyl, preferably cyclopropyl or oxetanyl, in each         case unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH,         O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue,     -   preferably in each case unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl and O—C₁₋₄-aliphatic residue, more         preferably in each case unsubstituted,         -   wherein the C₁₋₄-aliphatic residue in each case is             unsubstituted,     -   and wherein cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl,         oxetanyl, piperidinyl, tetrahydrofuranyl, and tetrahydropyranyl         may in each case be optionally linked via an unsubstituted         C₁₋₄-aliphatic group,     -   on the condition that if R⁵ or R⁶ denotes piperidinyl, oxetanyl,         tetrahydrofuranyl, or tetrahydropyranyl, each of these residues         is linked via a carbon atom, -   or -   R³ denotes N(R⁷R⁸),     -   wherein     -   R⁷ denotes C₁₋₆-aliphatic residue,         -   unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, ═O,             OH and OCH₃,         -   preferably unsubstituted or mono- or polysubstituted with at             least one substituent selected from the group consisting of             F, Cl and OCH₃,         -   more preferably unsubstituted or mono- or polysubstituted             with at least one substituent selected from the group             consisting of F and OCH₃,     -   preferably denotes unsubstituted C₁₋₆-aliphatic residue,     -   more preferably selected from the group consisting of CH₃,         CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, CH₂(CH₂)₂CH₃, CH₂CH(CH₃)₂,         CH(CH₃)CH₂CH₃, C(CH₃)₃, CH₂(CH₂)₃CH₃, CH₂CH₂CH(CH₃)₂, CH₂C(CH₃)₃         and CH₂(CH₂)₄CH₃,     -   and     -   R⁸ denotes CH₃, CH₂CH₃, CH₂CH₂CH₃, CH(CH₃)₂, CH₂(CH₂)₂CH₃,         CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃ or C(CH₃)₃,     -   more preferably CH₃ or CH₂CH₃     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl,     -   in each case unsubstituted or mono- or polysubstituted with at         least one substituent selected from the group consisting of F,         Cl, OH, O—C₁₋₄-aliphatic residue and C₁₋₄-aliphatic residue,     -   more preferably unsubstituted or mono- or polysubstituted with         at least one substituent selected from the group consisting of         F, Cl and O—C₁₋₄-aliphatic residue,     -   preferably form together with the nitrogen atom connecting them         a morpholinyl, piperidinyl, pyrrolidinyl, or azetidinyl, in each         case unsubstituted.

In a particular preferred embodiment of the present invention, the compound according to general formula (I) is characterized in that

-   R³ is selected from the group consisting of -   C₂H₅, CH₂CH₂CH₃, CH(CH₃)₂, CH₂CH₂CH₂CH₃, CH₂CH(CH₃)₂, CH(CH₃)CH₂CH₃,     C(CH₃)₃, CH₂-cyclopropyl, OCH₃, OC₂H₅, OCH₂CH₂CH₃, OCH(CH₃)₂,     O-cyclopropyl, SCH₃, SC₂H₅, SCH₂CH₂CH₃, SCH(CH₃)₂, S-cyclopropyl,     cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH₃)₂,     N(CH₃)C₂H₅, N(CH₃)CH₂CH₂CH₃, N(CH₃)CH(CH₃)₂, N(CH₃)-cyclopropyl,     N(C₂H₅)₂, N(C₂H₅)CH₂CH₂CH₃, N(C₂H₅)CH(CH₃)₂, N(C₂H₅)-cyclopropyl,     N-aziridinyl, N-azetidinyl, N-pyrrolidinyl, N-piperidinyl or     N-morpholinyl, -   in each case unsubstituted or mono- or polysubstituted with F, OH     and/or OCH₃.

In another embodiment of the invention, the compound according to general formula (I) is characterized in that

-   each R⁴ -   independently represents H, F, Cl, Br, I, CN, CF₃, CHF₂, CH₂F, OCF₃,     OCHF₂, OCH₂F, SCF₃, aliphatic residue, C₁₋₄-aliphatic residue or     S(═O)₂—C₁₋₄-aliphatic residue.

Preferably,

-   each R⁴ independently represents H, F, Cl, Br, CN, CF₃, OCF₃, CH₃,     OCH₃ or S(═O)₂CH₃.

More preferably,

-   each R⁴ independently represents H or CF₃.

In one preferred embodiment of the invention, each R⁴ represents H.

In another preferred embodiment of the invention, at least one R⁴ does not represent H.

In another preferred embodiment of the invention, at least one R⁴ represents CF₃.

In particularly preferred embodiment of the invention, the compound according to general formula (I) is characterized in that

-   A¹, A² and A³ independently of each other represent CR⁴, N, O, S or     N(CH₃), -   A⁴ represents CR⁴ or N, and -   n denotes 0 or 1, -   with the proviso, that -   at least one of A¹, A², A³ and A⁴ does not represent CR⁴, -   and with the proviso, that -   if n denotes 0, then precisely one of A¹, A² and A³ represents O, S     or N(CH₃), or -   if n denotes 1, then A¹, A² and A³ independently of each other     represent CR⁴ or N, -   R¹ represents the partial structure (T1),

-   -   wherein     -   m denotes 0, 1, or 2,     -   R^(1a) and R^(1b) each independently of one another represent H,         F, Cl, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue,     -   R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, O—C₁₋₄ aliphatic residue, CF₃ and         C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, CF₃             and O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, C₁₋₁₀—C₁₋₄-aliphatic residue,         CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, CF₃             and O—C₁₋₄-aliphatic residue,     -   or     -   denotes aryl or heteroaryl, in each case unsubstituted or mono-         or polysubstituted with at least one substituent selected from         the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue,         OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅,         C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7         membered heterocycloaliphatic residue, benzyl, phenyl, thienyl         or pyridyl,         -   wherein benzyl, phenyl, thienyl and pyridyl, may in each             case may be unsubstituted or mono- or polysubstituted with             at least one substituent selected from the group consisting             of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃,             CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃             and C(═O)OC₂H₅, and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃             C₁₋₄-aliphatic residue and C(═O)OH,

-   R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic     residue, S—C₁₋₄-aliphatic residue or O—C₁₋₄-aliphatic residue,     -   wherein the C₁₋₄-aliphatic residue in each case may be         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, ═O, OH         and O—C₁₋₄-aliphatic residue,

-   R³ denotes C₂₋₆-aliphatic residue, unsubstituted or mono- or     polysubstituted with at least one substituent selected from the     group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃,     SCF₃, CF₃ and C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with OH or             O—C₁₋₄-aliphatic residue, and         -   wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10             membered heterocycloaliphatic residue may in each case             optionally linked via a C₁₋₄-aliphatic group,

-   or

-   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case denote C₁₋₈-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   in each case denote C₃₋₈-cycloaliphatic residue or 3 to 7         membered heterocycloaliphatic residue, in each case         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and         -   wherein the C₃₋₈-cycloaliphatic residue or the 3 to 7             membered heterocycloaliphatic residue in each case may be             linked via an unsubstituted C₁₋₄-aliphatic group,     -   on the condition that if R⁵ or R⁶ denotes 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom,

-   or

-   R³ denotes N(R⁷R⁸),     -   wherein     -   R⁷ denotes C₁₋₈-aliphatic residue, unsubstituted or mono- or         polysubstituted with at least one substituent selected from the         group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue,         OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,     -   or     -   denotes C₃₋₈-cycloaliphatic residue or 3 to 7 membered         heterocycloaliphatic residue, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, C(═O)—O—C₁₋₄-aliphatic residue, CF₃ and         C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and         -   wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7             membered heterocycloaliphatic residue is in each case linked             via an unsubstituted C₁₋₄-aliphatic group,     -   on the condition that if R⁷ denotes 3 to 7 membered         heterocycloaliphatic residue, the 3 to 7 membered         heterocycloaliphatic residue is linked via a carbon atom,     -   and     -   R⁸ denotes unsubstituted C₁₋₄-aliphatic residue,     -   or     -   R⁷ and R⁸ form together with the nitrogen atom connecting them a         3 to 7 membered heterocycloaliphatic residue, unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic         residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue, and         -   wherein the 3 to 7 membered heterocycloaliphatic residue             formed by R⁷ and R⁸ together with the nitrogen atom             connecting them may optionally be condensed with phenyl or             pyridyl, wherein the phenyl or pyridyl residues condensed in             this way can for their part be respectively unsubstituted or             mono- or polysubstituted with at least one substituent             selected from the group consisting of F, Cl, OH,             O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN,             C₁₋₄-aliphatic residue, C(═O)OH, benzyl, phenyl, and             pyridyl,             -   wherein the C₁₋₄-aliphatic residue in each case may be                 unsubstituted or mono- or polysubstituted with at least                 one substituent selected from the group consisting of F,                 Cl, OH, and O—C₁₋₄-aliphatic residue, and wherein                 benzyl, phenyl, and pyridyl, may in each case may be                 unsubstituted or mono- or polysubstituted with at least                 one substituent selected from the group consisting of F,                 Cl, OCH₃, OCF₃, OCH₂CH₂OH, O CH₂CH₂OCH₃, SH, SCF₃, CF₃                 and C₁₋₄-aliphatic residue,

-   and

-   each R⁴ independently represents H, F, Cl, Br, CN, CF₃, OCF₃, CH₃,     OCH₃ or S(═O)₂CH₃.

In more particularly preferred embodiment of the invention, the compound according to general formula (I) is characterized in that

-   A¹, A² and A³ independently of each other represent CR⁴, N, O, S or     N(CH₃), -   A⁴ represents CR⁴ or N, and -   n denotes 0 or 1, -   with the proviso, that -   at least one of A¹, A², A³ and A⁴ does not represent CR⁴, -   and with the proviso, that -   if n denotes 0, then precisely one of A¹, A² and A³ represents O, S     or N(CH₃), or -   if n denotes 1, then A¹, A² and A³ independently of each other     represent CR⁴ or N, -   R¹ represents the partial structure (T1),

-   -   wherein     -   m denotes 0,     -   R^(1c) denotes aryl or heteroaryl, in each case unsubstituted or         mono- or polysubstituted with at least one substituent selected         from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic         residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃,         C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3         to 7 membered heterocycloaliphatic residue, benzyl, phenyl,         thienyl or pyridyl,         -   wherein benzyl, phenyl, thienyl and pyridyl, may in each             case may be unsubstituted or mono- or polysubstituted with             at least one substituent selected from the group consisting             of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃,             CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃             and C(═O)OC₂H₅, and         -   wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7             membered heterocycloaliphatic residue may in each case may             be unsubstituted or mono- or polysubstituted with at least             one substituent selected from the group consisting of F, Cl,             Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃             C₁₋₄-aliphatic residue and C(═O)OH,

-   R² represents F, Cl, CN, CF₃, OCF₃, CH₃, or OCH₃,

-   R³ denotes S—R⁵ or O—R⁶,     -   wherein     -   R⁵ and R⁶ in each case denote C₁₋₈-aliphatic residue,         unsubstituted or mono- or polysubstituted with at least one         substituent selected from the group consisting of F, Cl, OH, ═O,         O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic         residue,         -   wherein the C₁₋₄-aliphatic residue in each case may be             unsubstituted or mono- or polysubstituted with at least one             substituent selected from the group consisting of F, Cl, OH,             CF₃ and O—C₁₋₄-aliphatic residue,

-   and

-   each R⁴ independently represents H, F, C₁ or CF₃.

Especially particularly preferred are compounds according to general formula (I) selected from the group comprising:

-   1     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,5]naphthyridine-3-carboxylic     acid amide; -   2     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,5]naphthyridine-3-carboxylic     acid amide; -   3     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic     acid amide; -   4     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic     acid amide; -   5     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic     acid amide; -   6     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic     acid amide; -   7     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,8]naphthyridine-3-carboxylic     acid amide; -   8     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,8]naphthyridine-3-carboxylic     acid amide; -   9     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,8]naphthyridine-3-carboxylic     acid amide; -   10     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,8]naphthyridine-3-carboxylic     acid amide; -   11     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,6]naphthyridine-3-carboxylic     acid amide; -   12     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,6]naphthyridine-3-carboxylic     acid amide; -   13     2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic     acid amide; -   14     2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic     acid amide; -   15     5-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-7-methyl-thieno[3,2-b]pyridine-6-carboxylic     acid amide; -   16     6-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-thieno[2,3-b]pyridine-5-carboxylic     acid amide; -   17     5-Ethoxy-N-[(3-fluorophenyl)-methyl]-7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxylic     acid amide; -   18     6-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-2-(trifluoromethyl)-thieno[2,3-b]pyridine-5-carboxylic     acid amide;     in the form of a free compound, a solvate and/or a physiologically     acceptable salt, respectively as racemate, as individual     enantiomers, as individual diastereomers, as mixtures of the     enantiomers in any mixing ratio or as mixtures of the diastereomers     in any mixing ratio.

The compounds of the general formula (I) and corresponding stereoisomers and also the respective corresponding salts and solvates are toxicologically safe and are therefore suitable as pharmaceutical active ingredients in pharmaceutical compositions.

In another aspect, the present invention therefore further relates to a pharmaceutical composition containing at least one compound according to general formula (I), in each case if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemates or in the form of a mixture of stereoisomers, in particular the enantiomers and/or diastereomers, in any desired mixing ratio, or respectively in the form of a physiologically acceptable salt, or respectively in the form of a corresponding solvate, and also if appropriate one or more pharmaceutically acceptable auxiliaries.

These pharmaceutical compositions according to the invention are suitable in particular for the modulation of KCNQ2/3 K⁺ channels, preferably for KCNQ2/3 K⁺ channel inhibition and/or KCNQ2/3 K⁺ channel stimulation, i.e. they exert an agonistic or antagonistic effect.

Likewise, the pharmaceutical compositions according to the invention are preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K⁺ channels. The pharmaceutical composition according to the invention is suitable for administration to adults and children, including toddlers and babies.

The pharmaceutical composition according to the invention may be prepared as a liquid, semisolid or solid pharmaceutical form, for example in the form of injection solutions, drops, juices, syrups, sprays, suspensions, tablets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions, aerosols or in multiparticulate form, for example in the form of pellets or granules, if appropriate pressed into tablets, decanted in capsules or suspended in a liquid, and also be administered as much.

In addition to at least one substituted compound of general formula (I), if appropriate in the form of one of its pure stereoisomers, in particular enantiomers or diastereomers, its racemate or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, or if appropriate in the form of a corresponding salt or respectively in the form of a corresponding solvate, the pharmaceutical composition according to the invention conventionally may contain further physiologically acceptable pharmaceutical auxiliaries which, for example, can be selected from the group consisting of excipients, fillers, solvents, diluents, surface-active substances, dyes, preservatives, blasting agents, slip additives, lubricants, aromas and binders.

The selection of the physiologically acceptable auxiliaries and also the amounts thereof to be used depend on whether the pharmaceutical composition is to be applied orally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to infections of the skin, the mucous membranes and of the eyes. Preparations in the form of tablets, dragées, capsules, granules, pellets, drops, juices and syrups are preferably suitable for oral application; solutions, suspensions, easily reconstitutable dry preparations and also sprays are preferably suitable for parenteral, topical and inhalative application. The substituted compounds according to the invention used in the pharmaceutical composition according to the invention in a repository, in a dissolved form or in a plaster, and further agents promoting skin penetration being added if appropriate, are suitable percutaneous application preparations. Orally or percutaneously applicable preparation forms can release the respective substituted compound according to the invention also in a delayed manner.

The pharmaceutical compositions according to the invention can be prepared with the aid of conventional means, devices, methods and process known in the art, such as are described for example in “Remington's Pharmaceutical Sciences”, A. R. Gennaro (Editor), 17^(th) edition, Mack Publishing Company, Easton, Pa., 1985, in particular in Part 8, Chapters 76 to 93. The corresponding description is introduced herewith by way of reference and forms part of the disclosure. The amount to be administered to the patient of the respective substituted compounds according to the invention of the above-indicated general formula (I) may vary and is for example dependent on the patient's weight or age and also on the type of application, the indication and the severity of the disorder. Conventionally, 0.001 to 100 mg/kg, preferably 0.05 to 75 mg/kg, particularly preferably 0.05 to 50 mg of at least one compound according to the invention are applied per kg of the patient's body weight.

The pharmaceutical composition according to the invention is preferably suitable for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K⁺ channels. The pharmaceutical composition according to the invention is more preferably suitable for the treatment and/or prophylaxis of one or more diseases and/or disorders selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.

The pharmaceutical composition according to the invention is suitable particularly preferably for the treatment of pain, more particularly preferably of acute pain, chronic pain, neuropathic pain, visceral pain, inflammatory pain and muscular pain, and most particularly for the treatment of neuropathic pain.

The pharmaceutical composition according to the invention is also preferably suitable for the treatment and/or prophylaxis of epilepsy.

In a further aspect of the present invention, the invention therefore relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K⁺ channels.

Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, especially pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.

Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for the prophylaxis and/or treatment of epilepsy.

In another aspect of the invention, the present invention further relates to at least one compound according to general formula (I) and also if appropriate of one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for prophylaxis and/or treatment of disorders and/or diseases which are mediated, at least in part, by KCNQ2/3 K⁺ channels.

Preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias.

Particular preference is given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of disorders and/or diseases selected from the group consisting of pain, in particular pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, most particularly neuropathic pain.

Particular preference is also given to at least one compound according to general formula (I) and optionally one or more pharmaceutically acceptable auxiliaries for use in the preparation of a medicament for the prophylaxis and/or treatment of epilepsy.

Another aspect of the present invention is a method of treatment and/or prophylaxis of disorders and/or diseases, which are mediated, at least in part, by KCNQ2/3 K⁺ channels, in a mammal, preferably of disorders and/or diseases selected from the group consisting of pain, preferably pain selected from the group consisting of acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases and dystonia-associated dyskinesias, which comprises administering an effective amount of at least one compound of general formula (I) to the mammal.

The effectiveness against pain can be shown, for example, in the Bennett or Chung model (Bennett, G. J. and Xie, Y. K., A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain 1988, 33(1), 87-107; Kim, S. H. and Chung, J. M., An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 1992, 50(3), 355-363), by tail flick experiments (e.g. according to D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941)) or by the formalin test (e.g. according to D. Dubuisson et al., Pain 1977, 4, 161-174). The effectiveness against epilepsy can be demonstrated, for example, in the DBA/2 mouse model (De Sarro et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 363, 330-336).

The compounds according to the invention preferably have a EC₅₀ value of not more than 10000 nM or not more than 8000 nM, more preferably not more than 7000 nM or not more than 6000 nM, yet more preferably not more than 5000 nM or not more than 3000 nM, even more preferably not more than 2000 nM or not more than 1000 nM, yet even more preferably not more than 800 nM or not more than 700 nM, still more preferably not more than 600 nM or not more than 500 nM, yet still more preferably not more than 400 nM or not more than 300 nM, most preferably not more than 200 nM or not more than 150 nM and especially not more than 120 nM or not more than 100 nM. Methods for determining the EC₅₀ value are known to the person skilled in the art. The EC₅₀ value is preferably determined by fluorimetry, particularly preferably as described below under “pharmacological experiments”.

The invention further provides processes for the preparation of the substituted compounds according to the invention.

The chemicals and reaction components used in the reactions and schemes described below are available commercially or in each case can be prepared by conventional methods known to the person skilled in the art.

The reactions described can each be carried out under the conventional conditions with which the person skilled in the art is familiar, for example with regard to pressure or the order in which the components are added. If appropriate, the person skilled in the art can determine the optimum procedure under the respective conditions by carrying out simple preliminary tests. The intermediate and end products obtained using the reactions described hereinbefore can each be purified and/or isolated, if desired and/or required, using conventional methods known to the person skilled in the art. Suitable purifying processes are for example extraction processes and chromatographic processes such as column chromatography or preparative chromatography. All of the process steps described below, as well as the respective purification and/or isolation of intermediate or end products, can be carried out partly or completely under an inert gas atmosphere, preferably under a nitrogen atmosphere.

If the compounds according to general formula (I) are obtained, after preparation thereof, in the form of a mixture of their stereoisomers, preferably in the form of their racemates or other mixtures of their various enantiomers and/or diastereomers, they can be separated and if appropriate isolated using conventional processes known to the person skilled in the art. Examples include chromatographic separating processes, in particular liquid chromatography processes under normal pressure or under elevated pressure, preferably MPLC and HPLC processes, and also fractional crystallisation processes. These processes allow individual enantiomers, for example diastereomeric salts formed by means of chiral stationary phase HPLC or by means of crystallisation with chiral acids, for example (+)-tartaric acid, (−)-tartaric acid or (+)-10-camphorsulphonic acid, to be separated from one another.

The various, and in particular the preferred, embodiments of the first aspect of the present invention apply in analogous manner—mutatis mutandis—to the other aspects of the present invention.

The compounds according to invention may be prepared as shown in reaction schemes below:

A plurality of syntheses of and synthesis paths to compounds of the general formula SNS-001 with numerous residues R² and with a very broad substitution pattern for residues R⁴ in case of A¹, A², A³ or A⁴ represent CR⁴ are known in the current specialist literature. Previously unknown intermediates of the general formula SNS-001 with similar substitution patterns for residues R² and R⁴ as outlined below and whose syntheses are not described in greater detail, can be produced by the person skilled in the art according to these known methods or by combination of the known methods.

In stage-01 amino-ketones of the general formula SNS-01 can be transformed into amides of the general formula SNS-02, for example, with acid chlorides of the general formula Cl(C═O)—CH₂—(C═O)—O(Me/Et), according to methods known to the person skilled in the art, for example, by addition of a base, for example NEt₃.

In stage-02 amido-ketones of the general formula SNS-02 can be cyclized to quinolones of the general formula SNS-03, according to methods known to the person skilled in the art, for example, by addition of a base, for example, NaH or NaOEt in an appropriate solvents, for example, EtOH.

In stage-03 quinolones of the general formula SNS-03 can be transformed into quinolinethiones of the general formula SNS-04, according to methods known to the person skilled in the art, for example, by use of Lawesson's reagent.

In stage-04 quinolinethiones of the general formula SNS-04 can be transformed into 2-mercapto-quinolines of the general formula SNS-06, with compounds of the general formula X—R⁵, where X denotes a leaving group, for example Methylsulfonyl or a halide, for example, chlorine, according to methods known to the person skilled in the art, for example, by addition of a base, for example, K₂CO₃ or NEt₃.

In stage-05 quinolones of the general formula SNS-03 can be transformed into 2-chloro-quinolines of the general formula SNS-07, according to methods known to the person skilled in the art, for example, by use of POCl₃ reagent.

In stage-06 2-chloro-quinolines of the general formula SNS-07 can be transformed into 2-mercapto-quinolines of the general formula SNS-06, for example, with compounds of the general formula M-S—R⁵, where M denotes a hydrogen atom or a metal, for example, sodium or potassium, according to methods known to the person skilled in the art, for example, by addition of a base, for example, K₂CO₃ or NEt₃.

In stage-07 2-chloro-quinolines of the general formula SNS-07 can be transformed into 2-alkyoxy-quinolines of the general formula SNS-05, for example, with compounds of the general formula M-O—R⁵, where M denotes a hydrogen atom or a metal, for example, sodium or potassium, according to methods known to the person skilled in the art, for example, by addition of a base, for example, NaH or NaOH.

In stage-08 2-chloro-quinolines of the general formula SNS-07 can be transformed into 2-amino-quinolines of the general formula SNS-05, for with amines of the general formula HNR⁷R⁸ according to methods known to the person skilled in the art, for example, by adding a base, for example NEt₃.

In stage-09 2-chloro-quinolines of the general formulae SNS-07 be transformed into 2-alykl-quinolines of the general formula SNS-09, where R³ is attached via a carbon atom, with compounds of the general formula X—R³, where or X denotes a residue to form an organometal reagent, for example MgBr, MgCl or Bu₃Sn according to methods known to the person skilled in the art, optionally in the presence of a suitable base, for example NEt₃, DIPEA, K₂CO₃, Cs₂CO₃, NaOtBu or KOtBu, optionally by addition of a suitable coupling reagent, for example Pd(PPh₃)₄, Ni(dppp)Cl₂ or Fe(acac)₃.

In stage-10 quinolinones of the general formula SNS-04 can be transformed into 2-alkoxy-quinolines of the general formula SNS-06, with compounds of the general formula X—R⁶, where X denotes a leaving group, for example Methylsulfonyl or a halide, for example, chlorine, according to methods known to the person skilled in the art, for example, by addition of a base, for example, Ag₂CO₃, K₂CO₃ or NEt₃.

In stage-11 methyl or ethyl ester of the general formula SNS-10 can be transformed into the corresponding acid of the general formula SNS-11, according to methods known to the person skilled in the art, for example, by use of a base, for example, LiOH.

In stage-12 acids of the general formulae SNS-11 can be transformed into amides of the general formula I, with amines of the general formula R¹—CH₂—NH₂ according to methods known to the person skilled in the art, for example, by using a suitable coupling reagent, for example, HATU.

In stage-13 methyl or ethyl ester of the general formula SNS-10 can be transformed into amides of the general formula (I), with amines of the general formula R¹—CH₂—NH₂ according to methods known to the person skilled in the art, for example, by using a suitable coupling reagent, for example, trimethyl-alumina.

EXAMPLES

The indication “equivalents” (“eq.”) means molar equivalents, “RT” means room temperature (23±7° C.), “M” are indications of concentration in mol/l, “aq.” means aqueous, “sat.” means saturated, “sol.” means solution, “conc.” means concentrated.

FURTHER ABBREVIATIONS

-   brine saturated aqueous sodium chloride solution -   CC column chromatography on silica gel -   DCM dichloromethane -   DMF N,N-dimethylformamide -   EtOAc ethyl acetate -   h hour(s) -   HATU     O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate -   m/z mass-to-charge ratio -   LR Lawesson's reagent     (2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-dithione) -   min minutes -   MS mass spectrometry -   TEA triethylamine -   RM reaction mixture -   v/v volume to volume -   w/w weight in weight

The yields of the compounds prepared were not optimised. All temperatures are uncorrected. All starting materials which are not explicitly described were either commercially available (the details of suppliers such as for example Acros, Avocado, Aldrich, Bachem, Fluke, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.

The mixing ratios of solvents or eluents for chromatography are specified in v/v.

All the intermediate products and exemplary compounds were analytically characterised by means of ¹H-NMR spectroscopy. In addition, mass spectrometry tests (MS, m/z for [M+H]⁺) were carried out for all the exemplary compounds and selected intermediate products.

Synthesis of Exemplary Compounds Synthesis of Example 1 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide

a) Synthesis of ethyl 3-(2-acetyl-5-(trifluoromethyl)pyridin-3-ylamino)-3-oxopropanoate

To a solution of 1-(3-amino-5-(trifluoromethyl)pyridin-2-yl)ethanone (0.87 g, 4.26 mmol, 1 eq.) in DCM (20 ml) were added TEA (0.65 ml, 4.69 mmol, 1.1 eq.) and ethyl 3-chloro-3-oxopropanoate (0.71 ml, 5.54 mmol, 1.3 eq.) at 0° C. The reaction mixture was stirred at RT for 3 h. Then the mixture was diluted with water (50 ml) and extracted with DCM (3×80 ml). The combined organic layers were washed with water (80 ml), dried over anhydrous Na₂SO₄ and concentrated in vacuo to provide ethyl 3-(2-acetyl-5-(trifluoromethyl)pyridin-3-ylamino)-3-oxopropanoate (1.35 g, 4.24 mmol, 99%) which was used in subsequent reactions without further purification.

b) Synthesis of ethyl 2-hydroxy-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate

To a cooled (ice water batch) suspension of ethyl 3-(2-acetyl-5-(trifluoromethyl)pyridin-3-ylamino)-3-oxopropanoate (1.35 g, 4.24 mmol, 1 eq.) in ethanol (15 ml) was added NaH (60% w/w suspension in oil, 0.19 g, 4.66 mmol, 1.1 eq.) portion wise. The reaction mixture was stirred at RT for 1 h. Then the reaction was quenched with water (20 ml) and ethanol was distilled off. The residue was acidified with 5M aq. HCl (pH˜4) and was extracted with EtOAc (3×100 ml). The combined organic layers were washed with brine (100 ml), dried over anhydrous Na₂SO₄ and evaporated to provide the crude product, which was triturated with DCM (2×30 ml) to yield ethyl 2-hydroxy-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (1.05 g, 3.50 mmol, 82%).

c) Synthesis of ethyl 2-chloro-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate

To ethyl 2-hydroxy-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (1.05 g, 3.50 mmol, 1 eq.) was added POCl₃ (11 ml) at RT and the reaction mixture was heated to reflux at 110° C. for 3 h. Afterwards excess POCl₃ was distilled off and the residue was diluted with EtOAc (50 ml). The mixture was washed with a sat. solution of NaHCO₃ (50 ml), water (50 ml), brine (50 ml), dried over anhydrous Na₂SO₄ and evaporated to provide ethyl 2-chloro-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (0.98 g, 3.08 mmol, 88%), which was used in subsequent reactions without further purification.

d) Synthesis of ethyl 2-(ethylthio)-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate

To a solution of ethyl 2-chloro-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (0.97 g, 3.05 mmol, 1 eq.) in DMF (10 ml) were added K₂CO₃ (1.26 g, 9.15 mmol, 3 eq.) and ethanethiol (0.66 ml, 9.15 mmol, 3 eq.) at RT. The mixture was stirred at 60° C. for 16 h. Afterwards the mixture was diluted with water (80 ml) and was extracted with EtOAc (3×80 ml). The combined organic layers were washed with water (100 ml), brine (100 ml), dried over anhydrous Na₂SO₄ and evaporated to provide the crude product, which is purified by CC (EtOAc/hexane 1:9) to yield ethyl 2-(ethylthio)-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (0.75 g, 2.18 mmol, 71%).

e) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide

To a solution of ethyl 2-(ethylthio)-4-methyl-7-(trifluoromethyl)-1,5-naphthyridine-3-carboxylate (0.20 g, 0.58 mmol, 1 eq.) in toluene (6 ml) were added Me₃Al(2M solution in toluene, 1.16 ml, 2.32 mmol, 4 eq.) and (3-fluorophenyl)methanamine (0.27 ml, 2.32 mmol, 4 eq.) at RT. The reaction mixture was stirred at 110° C. for 16 h. Afterwards the mixture was diluted with water (50 ml) and was extracted with EtOAc (3×40 ml). The combined organic layers were washed with a 0.5 M aq. HCl (60 ml), brine (60 ml), dried over anhydrous Na₂SO₄ and evaporated to provide the crude product, which was purified by CC (EtOAc/hexane 1:4) to yield 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide (example 1) (0.14 g, 0.33 mmol, 57%). MS m/z [M+H]⁺ 424.1.

Synthesis of Example 2 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic acid amide

a) Synthesis of 2-(ethylthio)-4-methyl-1,7-naphthyridine-3-carboxylic acid

To a solution of ethyl 2-(ethylthio)-4-methyl-1,7-naphthyridine-3-carboxylate [synthesized according to the methods described for example 1, sections a-d] (2.30 g, 8.33 mmol, 1 eq) in a mixture of THF (30 ml) and methanol (15 ml) was added a solution of LiOH.H₂O (3.50 g, 83.33 mmol, 10 eq) in water (7.5 ml) at RT. The resulting mixture was stirred at 75° C. for 5 h. Afterwards the solvents were evaporated and the residue was washed with EtOAc (80 ml). The aq. layer was acidified with a 4M aq. HCl (50 ml) and extracted with EtOAc (3×100 ml). The combined organic layers were washed with water (100 ml), brine (100 ml), dried over anhydrous Na₂SO₄ and evaporated to provide 2-(ethylthio)-4-methyl-1,7-naphthyridine-3-carboxylic acid (0.85 g, 3.43 mmol, 41%) which was used in subsequent reactions without further purification.

b) Synthesis of 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic acid amide

To a solution of 2-(ethylthio)-4-methyl-1,7-naphthyridine-3-carboxylic acid (0.25 g, 1.01 mmol, 1 eq) in dry THF (12 ml) were added HATU (0.42 g, 1.11 mmol, 1.1 eq) and TEA (0.4 ml, 3.03 mmol, 3 eq) at RT and the reaction mixture was stirred at RT for 15 min. 3-fluorophenyl)methanamine (0.16 g, 1.26 mmol, 1.25 eq) was added to the mixture at RT and the reaction mixture was stirred at RT for 1 h. Afterwards the excess solvent was distilled off and the residue was diluted with a sat. aq. solution of NH₄Cl (50 ml). The aq. part was extracted with EtOAc (3×80 ml). The combined organic layers were washed with a sat. aq. solution of NaHCO₃ (50 ml), water (50 ml), dried over anhydrous Na₂SO₄ and evaporated to provide the crude product, which was purified by CC (acetone/hexane 2:9) to yield 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic acid amide (example 2) (0.18 g, 0.51 mmol, 50%). MS m/z [M+H]⁺ 356.1.

Synthesis of Example 3 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide

a) Synthesis of ethyl 2-mercapto-4-methyl-1,6-naphthyridine-3-carboxylate

To a solution of ethyl 2-hydroxy-4-methyl-1,6-naphthyridine-3-carboxylate [synthesized according to the methods described for example 1, sections a and b] (0.35 g, 1.51 mmol, 1 eq.) in a mixture of pyridine/toluene (1:9 v/v, 15 ml) was added LR (2.44 g, 6.03 mmol, 4 eq.) at RT and the reaction mixture was heated to reflux at 110° C. for 22 h. Afterwards the mixture was cooled to RT and was quenched with a sat. aq. solution of NaHCO₃ (5 ml). The aq. part was extracted with EtOAc (3×30 ml). The combined organic layers were washed with water (30 ml), brine (30 ml), dried over anhydrous Na₂SO₄ and evaporated to provide the crude product which is purified by CC (methanol/DCM 1:99) to yield ethyl 2-mercapto-4-methyl-1,6-naphthyridine-3-carboxylate (0.22 g, 0.89 mmol, 59%).

b) Synthesis of ethyl 2-(ethylthio)-4-methyl-1,6-naphthyridine-3-carboxylate

To a solution of ethyl 2-mercapto-4-methyl-1,6-naphthyridine-3-carboxylate (0.22 g, 0.89 mmol, 1 eq.) in dry DMF (5 ml) was added K₂CO₃ (0.37 g, 2.66 mmol, 3 eq.) at 0° C. followed by the addition of ethyl iodide (0.41 g, 2.66 mmol, 3 eq.). The reaction mixture was stirred at RT for 1 h. Afterwards the mixture was poured into ice water (10 ml) and extracted with EtOAc (3×20 ml). The combined organic layers were washed with water (20 ml), brine (20 ml), dried over anhydrous Na₂SO₄ to provide the crude product, which was purified by CC (EtOAc/hexane 2:3) to yield ethyl 2-(ethylthio)-4-methyl-1,6-naphthyridine-3-carboxylate (0.18 g, 0.65 mmol, 73%).

c) Synthesis of 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide

2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide (example 3) (0.18 g, 0.51 mmol, 50%) was synthesized from Ethyl 2-(ethylthio)-4-methyl-1,6-naphthyridine-3-carboxylate (0.20 g, 0.72 mmol, 1 eq.) according to the method described for example 1, section e. MS m/z [M+H]⁺ 356.1.

Synthesis of Example 4 6-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-thieno[2,3-b]pyridine-5-carboxylic acid amide

a) Synthesis of ethyl 4-methyl-6-(trifluoromethylsulfonyloxy)thieno[2,3-b]pyridine-5-carboxylate

To a solution of ethyl 6-hydroxy-4-methylthieno[2,3-b]pyridine-5-carboxylate [synthesized according to the methods described for example 1, sections a and b] (1.00 g, 4.21 mmol, 1 eq.) in DCM (35 ml) were added TEA (1.16 ml, 8.43 mmol, 2 eq.) and triflic anhydride (1.16 ml, 8.43 mmol, 2 eq.) at 0° C. The RM was stirred at RT for 2 h. Afterwards the mixture was diluted with DCM (100 ml) and the organic layer was washed with a sat. aq. NaHCO₃ solution (50 ml), water (50 ml) and brine (50 ml). The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The crude ethyl 4-methyl-6-(trifluoro-methyl-sulfonyloxy)thieno[2,3-b]pyridine-5-carboxylate (1.55 g, 4.21 mmol, 99%) was used in subsequent reactions without further purification.

b) Synthesis of ethyl 6-(ethylthio)-4-methylthieno[2,3-b]pyridine-5-carboxylate

To a solution of ethyl 4-methyl-6-(trifluoro-methyl-sulfonyloxy)thieno[2,3-b]pyridine-5-carboxylate (1.84 g, 4.9 mmol, 1 eq.) in DMF (30 ml) were added K₂CO₃ (2.70 g, 19.6 mmol, 4 eq.) and ethanethiol (3.73 ml, 49.8 mmol, 10 eq.) at RT. The reaction mixture was stirred at 80° C. for 2 h. Afterwards the mixture was diluted with water (50 ml) and was extracted with EtOAc (2×50 ml). The combined organic layers were washed with water (50 ml), brine (50 ml), dried over Na₂SO₄ and evaporated. The crude product was purified by CC (EtOAc/hexane 1:49) to yield ethyl 6-(ethylthio)-4-methylthieno[2,3-b]pyridine-5-carboxylate (0.26 g, 0.92 mmol, 19%).

c) Synthesis of 6-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-thieno[2,3-b]pyridine-5-carboxylic acid amide

6-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-thieno[2,3-b]pyridine-5-carboxylic acid amide (example 4) (0.23 g, 0.64 mmol, 63%) was synthesized from ethyl 6-(ethylthio)-4-methylthieno[2,3-b]pyridine-5-carboxylate (0.29 g, 1.01 mmol, 1 eq.) according to the method described for example 1, section e. MS m/z [M+H]⁺ 361.1.

Synthesis of Example 5 5-Ethoxy-N-[(3-fluorophenyl)-methyl]-7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxylic acid amide

a) Synthesis of ethyl 5-ethoxy-7-methyl-2-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxylate

To a suspension N-(3-fluorobenzyl)-5-hydroxy-7-methyl-2-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxamide (0.40 g, 1.31 mmol, 1 eq.) [synthesized according to the methods described for example 1, sections a and b] in a mixture DCM (10 ml) and DMF (0.5 ml) was added Ag₂CO₃ (0.90 g, 3.28 mmol, 2.5 eq.) at RT followed by the addition of ethyl iodide (0.54 ml, 6.55 mmol, 5 eq.). The resulting mixture was stirred at RT for 20 h. Afterwards the reaction mass was filtered through celite. The filtrate was extracted with DCM and the DCM layer was concentrated in vacuo to provide the crude product, which was purified by CC (EtOAc/hexane 1:17) to yield ethyl 5-ethoxy-7-methyl-2-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxylate (0.37 g, 1.11 mmol, 84%).

b) Synthesis of 5-Ethoxy-N-[(3-fluorophenyl)-methyl]-7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxylic acid amide

5-Ethoxy-N-[(3-fluorophenyl)-methyl]-7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxylic acid amide (example 5) (0.20 g, 0.48 mmol, 44%) was synthesized from ethyl 5-ethoxy-7-methyl-2-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxylate (0.37 g, 1.11 mmol, 1 eq.) according to the method described for example 1, section e. MS m/z [M+H]⁺ 413.1.

Synthesis of Further Exemplary Compounds

The synthesis of further examples was carried out according to the methods already described. Table 1 shows which compound was produced according to which method. It is evident to the person skilled in the art which educts and reagents were used in each case.

TABLE 1 Preparation Yield [%] in analogy MS m/z Yield (final Example Chemical Name to example [M + H]⁺ [g] step) 6 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 1 424.1 0.06 48 4-methyl-7-(trifluoromethyl)- [1,8]naphthyridine-3-carboxylic acid amide 7 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 1 424.1 0.10 81 4-methyl-7-(trifluoromethyl)- [1,8]naphthyridine-3-carboxylic acid amide 8 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 1 356.1 0.09 69 4-methyl-[1,5]naphthyridine-3-carboxylic acid amide 9 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 1 356.1 0.15 46 4-methyl-[1,5]naphthyridine-3-carboxylic acid amide 10 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 1 424.1 0.18 48 4-methyl-7-(trifluoromethyl)- [1,5]naphthyridine-3-carboxylic acid amide 11 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 1 424.1 0.22 81 4-methyl-7-(trifluoromethyl)- [1,6]naphthyridine-3-carboxylic acid amide 12 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 1 424.1 0.30 91 4-methyl-7-(trifluoromethyl)- [1,6]naphthyridine-3-carboxylic acid amide 13 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 1 356.1 0.11 66 4-methyl-[1,6]naphthyridine-3-carboxylic acid amide 14 5-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 1 361.1 0.09 62 7-methyl-thieno[3,2-b]pyridine-6-carboxylic acid amide 15 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 2 356.1 0.11 42 4-methyl-[1,7]naphthyridine-3-carboxylic acid amide 16 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]- 2 356.1 0.11 26 4-methyl-[1,8]naphthyridine-3-carboxylic acid amide 17 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]- 2 356.1 0.11 26 4-methyl-[1,8]naphthyridine-3-carboxylic acid amide 18 6-Ethoxy-N-[(3-fluorophenyl)-methyl]-4- 5 413.1 0.05 46 methyl-2-(trifluoromethyl)-thieno[2,3- b]pyridine-5-carboxylic acid amide Pharmacological Experiments Method I. Fluorescence Assay Using a Voltage Sensitive Dye

Human CHO—K1 cells expressing KCNQ2/3 channels are cultivated adherently at 37° C., 5% CO₂ and 95% humidity in cell culture bottles (e.g. 80 cm² TC flasks, Nunc) with DMEM-high glucose (Sigma Aldrich, D7777) including 10% FCS (PAN Biotech, e.g. 3302-P270521) or alternatively MEM Alpha Medium (lx, liquid, Invitrogen, #22571), 10% fetal calf serum (FCS) (Invitrogen, #10270-106, heat-inactivated) and the necessary selection antibiotics.

Before being sown out for the measurements, the cells are washed with a 1×DPBS buffer without Ca²⁺/Mg²⁺ (e.g. Invitrogen, #14190-094) and detached from the bottom of the culture vessel by means of Accutase (PAA Laboratories, #L11-007) (incubation with Accutase for 15 min at 37° C.). The cell count then present is determined using a CASY™ cell counter (TCC model, Scharfe System) in order subsequently to apply, depending on the density optimization for the individual cell line, 20,000-30,000 cells/well/100 μl of the described nutrient medium to 96-well measuring plates of the Corning™ CeIIBIND™ type (Flat Clear Bottom Black Polystyrene Microplates, #3340). Incubation is then carried out for one hour at room temperature, without gassing or adjusting the humidity, followed by incubation for 24 hours at 37° C., 5% CO₂ and 95% humidity.

The voltage-sensitive fluorescent dye from the Membrane Potential Assay Kit (Red™ Bulk format part R8123 for FLIPR, MDS Analytical Technologies™) is prepared by dissolving the contents of a vessel Membrane Potential Assay Kit Red Component A in 200 ml of extracellular buffer (ES buffer, 120 mM NaCl, 1 mM KCl, 10 mM HEPES, 2 mM CaCl₂, 2 mM MgCl₂, 10 mM glucose; pH 7.4). After removal of the nutrient medium, the cells are washed with 200 μl of ES buffer, then covered with a layer of 100 μl of the dye solution prepared above and incubated for 45 min at room temperature with the exclusion of light.

The fluorescence measurements are carried out with a BMG Labtech FLUOstar™, BMG Labtech NOVOstar™ or BMG Labtech POLARstar™ instrument (525 nm excitation, 560 nm emission, Bottom Read mode). After incubation of the dye, 50 μl of the test substances in the desired concentrations, or 50 μl of ES buffer for control purposes, are introduced into separate cavities of the measuring plate and incubated for 30 min at room temperature while being shielded from light. The fluorescence intensity of the dye is then measured for 5 min and the fluorescence value F₁ of each well is thus determined at a given, constant time. 15 μl of a 100 mM KCl solution (final concentration 92 mM) are then added to each well. The change in fluorescence is subsequently measured until all the relevant measured values have been obtained (mainly 5-30 min). At a given time after KCl application, a fluorescence value F₂ is determined, in this case at the time of the fluorescence peak.

For calculation, the fluorescence intensity F₂ is corrected for the fluorescence intensity F₁, and the activity (ΔF/F) of the target compound on the potassium channel is determined as follows:

${\left( \frac{F_{2} - F_{1}}{F_{1}} \right) \times 100} = {\frac{\Delta\; F}{F}(\%)}$

In order to determine whether a substance has agonistic activity,

$\frac{\Delta\; F}{F}$ can be related to

$\left( \frac{\Delta\; F}{F} \right)_{K}$ of control wells.

$\left( \frac{\Delta\; F}{F} \right)_{K}$ is determined by adding to the well only the buffer solution instead of the test substance, determining the value F_(1K) of the fluorescence intensity, adding the potassium ions as described above, and measuring a value F_(2K) of the fluorescence intensity. F_(2K) and F_(1K) are then calculated as follows:

${\left( \frac{F_{2K} - F_{1K}}{F_{1K}} \right) \times 100} = {\left( \frac{\Delta\; F}{F} \right)_{K}(\%)}$

A substance has an agonistic activity on the potassium channel if

$\frac{\Delta\; F}{F}$ is greater than

$\left( \frac{\Delta\; F}{F} \right)_{K}:{\frac{\Delta\; F}{F} > \left( \frac{\Delta\; F}{F} \right)_{K}}$

Independently of the comparison of

$\frac{\Delta\; F}{F}\mspace{14mu}{with}\mspace{14mu}\left( \frac{\Delta\; F}{F} \right)_{K}$ it is possible to conclude that a target compound has agonistic activity if

$\frac{\Delta\; F}{F}$ increases dose dependently.

Calculations of EC₅₀ and IC₅₀ values are carried out with the aid of ‘Prism v4.0’ software (GraphPad Software™)

Method II. Low-Intensity Tail Flick Test (Rat)

In the low-intensity tail flick test, the determination of the antinociceptive effect of the compounds according to the invention towards an acute noxious thermal stimulus is carried out by measuring the withdrawal reflex of the rat tail (tail flick) in response to a radiant heat beam (analgesia meter; model 2011 of the company Rhema Labortechnik, Hofheim, Germany) according to the method described by D'Amour and Smith (J. Pharm. Exp. Ther. 72, 74 79 (1941). To this end, the rats were placed in a plexiglas restrainer, and a low-intensity radiant heat beam (48° C.) was focused onto the dorsal surface of the tail root. The stimulus intensity was adjusted to result in a mean pre-drug control withdrawal latency of about 7 s, thus also allowing a supraspinal modulation of the spinally mediated acute nociceptive reflex. A cutoff time of 30 s was applied to avoid tissue damage. Male Sprague-Dawley rats (Janvier, Le Genest St. Isle, Frankreich) with weights of 200-250 g were used. 10 rats were used per group. Before administration of a compound according to the invention, the animals were pre-tested twice in the course of five minutes and the mean of these measurements was calculated as the pre-test mean. The antinociceptive effect was determined at 20, 40 and 60 min after peroral compound administration. The antinociceptive effect was calculated based on the increase in the tail withdrawal latency according to the following formula and is expressed as percentage of the maximum possible effect (MPE [%]): MPE=[(T ₁ −T ₀)/(T ₂ −T ₀)]*100

In this, T₀ is the control latency time before and T₁ the latency time after administration of the compound, T₂ is the cutoff time and MPE is the maximum possible effect. Employing variant analysis (repeated measures ANOVA) allowed testing of statistically significant differences between the compounds according to the invention and the vehicle group. The significance level was set to p≦0.05.

Pharmacological Data

The pharmacological effects of the compounds according to the invention were determined as described hereinbefore (pharmacological experiments, methods I and II respectively).

The corresponding pharmacological data are summarized in Table 2.

TABLE 2 Low intensity Fluorimetry Fluorimetry tail flick, rat, % efficacy EC₅₀ peroral, ED₅₀ or MPE Example (retigabine = 100%) [nM] (dose) [mg/kg] 1 156 84 2 62 2193 3 34 4 31 5 121 51 6 152 683 7 132 412 16 (10) 8 9 9 6 10 148 101 11 101 201 12 97 301 13 32 14 −39 650 15 34 16 10 17 10 18 112 63 

The invention claimed is:
 1. A compound of general formula (I)

wherein A¹, A² and A³ independently of each other represent CR⁴, N, O, S or N(CH₃), A⁴ represents CR⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A¹, A², A³ and A⁴ does not represent CR⁴, and with the proviso, that if n denotes 0, then precisely one of A¹, A² and A³ represents O, S or N(CH₃), or if n denotes 1, then A¹, A² and A³ independently of each other represent CR⁴ or N, R¹ represents C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C(═O)—NH—C₁₋₄-aliphatic residue, C(═O)—N(C₁₋₄-aliphatic residue)₂, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted;  C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R³ represents C₂₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,  or  denotes S—R⁵, O—R⁶ or N(R⁷R⁸),  wherein R⁵ and R⁶ in each case represent C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso, that if R⁵ or R⁶ denote a 3 to 10 membered heterocycloaliphatic residue, than the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, R⁷ represents C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso that if R⁷ denotes 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom; and R⁸ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; or R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; and each R⁴ independently represents H, F; Cl; Br; I; CN; CF₃; CHF₂; CH₂F; OCF₃; OCHF₂; OCH₂F; SCF₃; O—C₁₋₄-aliphatic residue, C₁₋₄-aliphatic residue or S(═O)₂—C₁₋₄-aliphatic residue; in which an “aliphatic group” and “aliphatic residue” may in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” may in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue, NH—S(═O)₂—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, CHO, COON, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(═O)NH₂, a C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,

 NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄-aliphatic residue, N(C₁₋₄ aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue, NH—S(═O)₂—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-S(═O)₂—C₁₋₄ aliphatic residue, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, C(═O)H, C(═O)OH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH₂, C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and and/or a physiologically acceptable salt.
 2. The compound according to claim 1, wherein A¹, A² and A³ independently of each other represent CR⁴, N, O, S or N(CH₃), A⁴ represents CR⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A¹, A², A³ and A⁴ does not represent CR⁴, and with the proviso, that if n denotes 0, then precisely one of A¹, A² and A³ represents O, S or N(CH₃), or if n denotes 1, then A¹, A² and A³ independently of each other represent CR⁴ or N, R¹ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  or denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH, C₃₋₆-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  or denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue,

 benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  and wherein the aryl or the heteroaryl residue may in each case be optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN and C(═O)OH, R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; O₁₄-aliphatic residue, S—C₁₋₄-aliphatic residue, O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  or  C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN and C(═O)OH, R³ denotes C₂₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, or  denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  or  denotes S—R⁵, O—R⁶ or N(R⁷R⁸),  wherein  R⁵ and R⁶ in each case represent C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  or in each case represent C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH, C₃₋₆-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  on the condition that if R⁵ or R⁶ denote a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,  R⁷ denotes a C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and an unsubstituted O—C₁₋₄-aliphatic residue,  or denotes a C₃₋₁₀-cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH,  on the condition that if R⁷ denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom,  and  R⁸ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  or  R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)—OH, C₃₋₆-cycloaliphatic residue and 3 to 7 membered heterocycloaliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R⁷ and R⁸ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue,

 benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein benzyl, phenyl, thienyl, pyridyl, furyl, thiazolyl and oxazolyl may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and wherein the C₃₋₆ cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)—OH, and each R⁴ independently represents H, F, Cl, Br, I, CN, CF₃, CHF₂, CH₂F, OCF₃, OCHF₂, OCH₂F, SCF₃, O—C₁₋₄-aliphatic residue, C₁₋₄-aliphatic residue or S(═O)₂—C₁₋₄-aliphatic residue.
 3. The compound according to claim 1, wherein n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents CR⁴; or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents CR⁴ and A⁴ represents CR⁴; or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents N and A⁴ represents CR⁴; or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents N; or n denotes 1 and A¹ represents N, A² represents N, A³ represents CR⁴ and A⁴ represents CR⁴; or n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents N and A⁴ represents CR⁴; or n denotes 1 and A¹ represents N, A² represents CR⁴, A³ represents CR⁴ and A⁴ represents N; or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents N and A⁴ represents CR⁴; or n denotes 1 and A¹ represents CR⁴, A² represents N, A³ represents CR⁴ and A⁴ represents N; or n denotes 1 and A¹ represents CR⁴, A² represents CR⁴, A³ represents N and A⁴ represents N; or n denotes 0 and A¹ represents CR⁴, A² represents CR⁴, and A³ represents S; or n denotes 0 and A¹ represents N, A² represents CR⁴, and A³ represents S; or n denotes 0 and A¹ represents S, A² represents CR⁴ and A³ represents CR⁴; or n denotes 0 and A¹ represents S, A² represents CR⁴ and A³ represents N.
 4. The compound according to claim 1, wherein R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue or O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH and O—C₁₋₄-aliphatic residue.
 5. The compound according to claim 1, wherein R² represents C₁₋₄-aliphatic residue.
 6. The compound according to claim 1, wherein each R⁴ independently represents H; F; Cl; Br; CN; CF₃; OCF₃; CH₃, OCH₃ or S(═O)₂CH₃.
 7. The compound according to claim 1, wherein R¹ represents the partial structure (T1),

wherein m denotes 0, 1, or 2, R^(1a) and R^(1b) each independently of one another represent H, F, Cl, Br, I, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and wherein the C₃₋₆ cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃ C₁₋₄-aliphatic residue and C(═O)OH.
 8. The compound according to claim 7, wherein m denotes 1 or 2, R^(1a) and R^(1b) represent H, R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue,  or  denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, or m denotes 0 and R^(1c) denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄aliphatic residue, OCF₃, CF₃, C₁₋₄-aliphatic residue and C(═O)OH.
 9. The compound according to claim 1, wherein R³ denotes a C₂₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, CF₃, CN and C₁₋₄-aliphatic residue wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, (═O)—O—C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue, CF₃, CN and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the C₃₋₇-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue, or R³ denotes S—R⁵ or O—R⁶,  wherein  R⁵ and R⁶ in each case denote C₁₋₈-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SH, SCF₃, S—C₁₋₄-aliphatic residue, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, CF₃ and C₁₋₄-aliphatic residue wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may be linked via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN and C₁₋₄-aliphatic residue,  on the condition that if R⁵ or R⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R³ denotes N(R⁷R⁸),  wherein  R⁷ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case be linked, via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue,  on the condition that if R⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom,  and  R⁸ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the 3 to 10 membered heterocycloaliphatic residue formed by R⁷ and R⁸ together with the nitrogen atom connecting them may optionally be condensed with aryl or heteroaryl, wherein the aryl or heteroaryl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, C₃₋₆ cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue,

 benzyl, phenyl, thienyl, and pyridyl, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein benzyl, phenyl, thienyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, OCH₂CH₂OH, OCH₂OCH₃, SCF₃, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue and C(═O)OH.
 10. The compound according to claim 1, wherein R³ denotes C₂₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,  or  denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or O—C₁₋₄-aliphatic residue,  and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₄-aliphatic group, or R³ denotes S—R⁵ or 0-R⁶,  wherein  R⁵ and R⁶ in each case denote C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue in each case may be linked via an unsubstituted C₁₋₄-aliphatic group, on the condition that if R⁵ or R⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R³ denotes N(R⁷R⁸), wherein R⁷ denotes C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue is in each case linked via a unsubstituted C₁₋₄-aliphatic group,  on the condition that if R⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R⁸ denotes unsubstituted C₁₋₄-aliphatic residue, or R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  and wherein the 3 to 7 membered heterocycloaliphatic residue formed by R⁷ and R⁸ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, benzyl, phenyl, and pyridyl, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH and O—C₁₋₄-aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OCH₃, OCF₃, OCH₂CH₂OH, OCH₂CH₂OCH₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue.
 11. The compound according to claim 1, wherein A¹, A² and A³ independently of each other represent CR⁴, N, O, S or N(CH₃), A⁴ represents CR⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A¹, A², A³ and A⁴ does not represent CR⁴, and with the proviso, that if n denotes 0, then precisely one of A¹, A² and A³ represents 0, S or N(CH₃), or if n denotes 1, then A¹, A² and A³ independently of each other represent CR⁴ or N, R¹ represents the partial structure (T1),

wherein m denotes 0, 1, or 2, R^(1a) and R^(1b) each independently of one another represent H, F, Cl, O—C₁₋₄-aliphatic residue or C₁₋₄-aliphatic residue, R^(1c) denotes C₁₋₄-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, O—C₁₋₄ aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl, wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅, and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, CF₃ C₁₋₄-aliphatic residue and C(═O)OH, R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue or O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, ═O, OH and O—C₁₋₄-aliphatic residue, R³ denotes C₂₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue,  or  denotes C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or O—C₁₋₄-aliphatic residue, and wherein the C₃₋₁₀-cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally linked via a C₁₋₄-aliphatic group, or R³ denotes S—R⁵ or O—R⁶,  wherein  R⁵ and R⁶ in each case denote C₁₋₈-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue in each case may be linked via an unsubstituted C₁₋₄-aliphatic group,  on the condition that if R⁵ or R⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, or R³ denotes N(R⁷R⁸), wherein R⁷ denotes C₁₋₈-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue,  or  denotes C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, C(═O)—O—C₁₋₄-aliphatic residue, CF₃ and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue is in each case linked via an unsubstituted C₁₋₄-aliphatic group,  on the condition that if R⁷ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom, and R⁸ denotes unsubstituted C₁₋₄-aliphatic residue, or R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 7 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN and C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue, and wherein the 3 to 7 membered heterocycloaliphatic residue formed by R⁷ and R⁸ together with the nitrogen atom connecting them may optionally be condensed with phenyl or pyridyl, wherein the phenyl or pyridyl residues condensed in this way can for their part be respectively unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)OH, benzyl, phenyl, and pyridyl, wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, and O—C₁₋₄-aliphatic residue, and wherein benzyl, phenyl, and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OCH₃, OCF₃, OCH₂CH₂OH, O CH₂CH₂OCH₃, SH, SCF₃, CF₃ and C₁₋₄-aliphatic residue, and each R⁴ independently represents H, F, Cl, Br, CN, CF₃, OCF₃, CH₃, OCH₃ or S(═O)₂CH₃.
 12. A compound selected from the group consisting of: 1 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,5]naphthyridine-3-carboxylic acid amide; 2 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,5]naphthyridine-3-carboxylic acid amide; 3 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide; 4 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide; 5 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic acid amide; 6 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,7]naphthyridine-3-carboxylic acid amide; 7 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,8]naphthyridine-3-carboxylic acid amide; 8 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-[1,8]naphthyridine-3-carboxylic acid amide; 9 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,8]naphthyridine-3-carboxylic acid amide; 10 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,8]naphthyridine-3-carboxylic acid amide; 11 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,6]naphthyridine-3-carboxylic acid amide; 12 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,6]naphthyridine-3-carboxylic acid amide; 13 2-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide; 14 2-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-7-(trifluoromethyl)-[1,5]naphthyridine-3-carboxylic acid amide; 15 5-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-7-methyl-thieno[3,2-b]pyridine-6-carboxylic acid amide; 16 6-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-thieno[2,3-b]pyridine-5-carboxylic acid amide; 17 5-Ethoxy-N-[(3-fluorophenyl)-methyl]-7-methyl-2-(trifluoromethyl)-thieno[3,2-b]pyridine-6-carboxylic acid amide; and 18 6-Ethoxy-N-[(3-fluorophenyl)-methyl]-4-methyl-2-(trifluoromethyl)-thieno[2,3-b]pyridine-5-carboxylic acid amide; in the form of a free compound, a solvate and and/or a physiologically acceptable salt.
 13. A pharmaceutical composition comprising at least one compound according to claim 1 in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a solvate and and/or a salt of physiologically acceptable acid or base, and optionally at least one pharmaceutically acceptable auxiliary and/or optionally at least one further active ingredient.
 14. A compound of general formula (I):

wherein A¹, A² and A³ independently of each other represent CR⁴, N, O, S or N(CH₃), A⁴ represents CR⁴ or N, and n denotes 0 or 1, with the proviso, that at least one of A¹, A², A³ and A⁴ does not represent CR⁴, and with the proviso, that if n denotes 0, then precisely one of A¹, A² and A³ represents O, S or N(CH₃), or if n denotes 1, then A¹, A² and A³ independently of each other represent CR⁴ or N, R¹ represents C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R² represents F; Cl; Br; I; CN; CF₃; C(═O)H; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C(═O)—NH—C₁₋₄-aliphatic residue, C(═O)—N(C₁₋₄-aliphatic residue)₂, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, wherein the C₁₋₄-aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted;  C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₄-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R³ represents C₂₋₁₀-aliphatic residue, mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted,  or  denotes S—R⁵, O—R⁶ or N(R⁷R⁸),  wherein R⁵ and R⁶ in each case represent C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso, that if R⁵ or R⁶ denote a 3 to 10 membered heterocycloaliphatic residue, than the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, R⁷ represents C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; C₃₋₁₀-cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally linked via a C₁₋₈-aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; with the proviso that if R⁷ denotes 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom; and R⁸ denotes C₁₋₁₀-aliphatic residue, unsubstituted or mono- or polysubstituted; or R⁷ and R⁸ form together with the nitrogen atom connecting them a 3 to 10 membered heterocycloaliphatic residue, unsubstituted or mono- or polysubstituted; and each R⁴ independently represents H, F; Cl; Br; I; CN; CF₃; CHF₂; CH₂F; OCF₃; OCHF₂; OCH₂F; SCF₃; O—C₁₋₄-aliphatic residue, C₁₋₄-aliphatic residue or S(═O)₂—C₁₋₄-aliphatic residue; in which an “aliphatic group” and “aliphatic residue” may in each case be branched or unbranched, saturated or unsaturated, in which a “cycloaliphatic residue” and a “heterocycloaliphatic residue” may in each case be saturated or unsaturated, in which “mono- or polysubstituted” with respect to an “aliphatic group”, an “aliphatic residue”, a “cycloaliphatic residue” and a “heterocycloaliphatic residue” relates, with respect to the corresponding residues or groups, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂, NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue, NH—S(═O)₂—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-S(═O)₂—C₁₋₄ aliphatic residue, ═O, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, CHO, COON, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, C(═O)NH₂, a C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; in which “mono- or polysubstituted” with respect to “aryl” and a “heteroaryl” relates, with respect to the corresponding residues, to the substitution of one or more hydrogen atoms each independently of one another by at least one substituent selected from the group consisting of F, Cl, Br, I, NO₂, NH₂,

 NH(C₁₋₄-aliphatic residue), N(C₁₋₄-aliphatic residue)₂, NH—C(═O)—C₁₋₄-aliphatic residue, N(C₁₋₄ aliphatic residue)-C(═O)—C₁₋₄ aliphatic residue, NH—S(═O)₂—C₁₋₄ aliphatic residue, N(C₁₋₄ aliphatic residue)-S(═O)₂—C₁₋₄ aliphatic residue, OH, OCF₃, O—C₁₋₄-aliphatic residue, O—C(═O)—C₁₋₄-aliphatic residue, SH, SCF₃, S—C₁₋₄-aliphatic residue, S(═O)₂OH, S(═O)₂—C₁₋₄-aliphatic residue, S(═O)₂—O—C₁₋₄-aliphatic residue, S(═O)₂—NH(C₁₋₄-aliphatic residue), S(═O)₂—N(C₁₋₄-aliphatic residue)₂, CN, CF₃, C(═O)H, C(═O)OH, C₁₋₄-aliphatic residue, C(═O)—C₁₋₄-aliphatic residue, C(═O)—O—C₁₋₄-aliphatic residue, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, aryl, heteroaryl, C(═O)NH₂, C(═O)—NH(C₁₋₄-aliphatic residue) and C(═O)—N(C₁₋₄-aliphatic residue)₂; in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a free compound, a solvate and and/or a physiologically acceptable salt.
 15. The compound according to claim 1, wherein: A¹, A² and A³ independently of each other represent CR⁴, N, O, S or N(CH₃); A⁴ represents CR⁴ or N; and n denotes 0 or 1; with the proviso, that at least one of A¹, A², A³ and A⁴ does not represent CR⁴; and with the proviso, that if n denotes 0, then precisely one of A¹, A² and A³ represents O, S or N(CH₃); or if n denotes 1, then A¹, A² and A³ independently of each other represent CR⁴ or N; R¹ denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃, C(═O)OC₂H₅, C₃₋₆-cycloaliphatic residue, 3 to 7 membered heterocycloaliphatic residue, benzyl, phenyl, thienyl or pyridyl; wherein benzyl, phenyl, thienyl and pyridyl, may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, O—C₁₋₄-aliphatic residue, OCF₃, CF₃, CN, C₁₋₄-aliphatic residue, C(═O)CH₃, C(═O)C₂H₅, C(═O)OCH₃ and C(═O)OC₂H₅; and wherein the C₃₋₆-cycloaliphatic residue and the 3 to 7 membered heterocycloaliphatic residue may in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ═O, O—C₁₋₄aliphatic residue, OCF₃, CF₃, C₁₋₄-aliphatic residue and C(═O)OH; R² represents F; Cl; Br; I; CN; CF₃; NO₂; OCF₃; SCF₃; C₁₋₄-aliphatic residue, S—C₁₋₄-aliphatic residue or O—C₁₋₄-aliphatic residue; wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ═O, OH and O—C₁₋₄-aliphatic residue; R³ denotes S—R⁵ or O—R⁶,  wherein  R⁵ and R⁶ in each case denote C₁₋₆-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue; wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, CF₃ and O—C₁₋₄-aliphatic residue;  or  in each case denote C₃₋₆-cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ═O, O—C₁₋₄-aliphatic residue, OCF₃, SCF₃, CF₃ and C₁₋₄-aliphatic residue; wherein the C₁₋₄-aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, OCF₃, CF₃ and O—C₁₋₄-aliphatic residue; and wherein the C₃₋₆-cycloaliphatic residue or the 3 to 7 membered heterocycloaliphatic residue in each case may be linked via an unsubstituted C₁₋₄-aliphatic group;  on the condition that if R⁵ or R⁶ denotes 3 to 7 membered heterocycloaliphatic residue, the 3 to 7 membered heterocycloaliphatic residue is linked via a carbon atom; and each R⁴ independently represents H; F; Cl; Br; CN; CF₃; OCF₃; CH₃, OCH₃ or S(═O)₂CH₃.
 16. A pharmaceutical composition comprising at least one compound according to claim 12 in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a solvate and and/or a salt of physiologically acceptable acid or base, and optionally at least one pharmaceutically acceptable auxiliary and/or optionally at least one further active ingredient.
 17. A pharmaceutical composition comprising at least one compound according to claim 14 in the form of an individual single stereoisomer or a mixture of the stereoisomers in any mixing ratio, and/or in the form of a solvate and and/or a salt of physiologically acceptable acid or base, and optionally at least one pharmaceutically acceptable auxiliary and/or optionally at least one further active ingredient.
 18. A method for treatment of a disorder and/or disease selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, said method comprising administering to a patient in need of such treatment an effective amount therefor of a compound according to claim
 1. 19. A method for treatment of a disorder and/or disease selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, said method comprising administering to a patient in need of such treatment an effective amount therefor of a compound according to claim
 12. 20. A method for treatment of a disorder and/or disease selected from the group consisting of pain, acute pain, chronic pain, neuropathic pain, muscular pain, visceral pain and inflammatory pain, said method comprising administering to a patient in need of such treatment an effective amount therefor of a compound according to claim
 14. 